Graduate Theses, Dissertations, and Problem Reports
2016

Assessment of molecular action of direct gating and allosteric
modulatory effects of meprobamate (MiltownRTM) on GABA A
receptors
Manish Kumar

Follow this and additional works at: https://researchrepository.wvu.edu/etd

Recommended Citation
Kumar, Manish, "Assessment of molecular action of direct gating and allosteric modulatory effects of
meprobamate (MiltownRTM) on GABA A receptors" (2016). Graduate Theses, Dissertations, and Problem
Reports. 6023.
https://researchrepository.wvu.edu/etd/6023

This Dissertation is protected by copyright and/or related rights. It has been brought to you by the The Research
Repository @ WVU with permission from the rights-holder(s). You are free to use this Dissertation in any way that is
permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain
permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license
in the record and/ or on the work itself. This Dissertation has been accepted for inclusion in WVU Graduate Theses,
Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU.
For more information, please contact researchrepository@mail.wvu.edu.

ASSESSMENT OF MOLECULAR ACTION OF DIRECT GATING AND
ALLOSTERIC MODULATORY EFFECTS OF CARISOPRODOL (SOMA®) ON
GABAA RECEPTORS
By
Manoj Kumar, B.Pharm.

Dissertation submitted to the School of Pharmacy at
West Virginia University in partial fulfillment of
the requirements for degree of

DOCTOR OF PHILOSOPHY
IN
PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES

COMMITTEE MEMBERS
Glenn H. Dillon, PhD., Chair
Jason D. Huber, PhD
Patrick S. Callery, PhD
Gregory M. Dick, PhD
Robert K Griffith, PhD

Department of Pharmaceutical Sciences
Morgantown, West Virginia
May 2015
Copyright 2015
Keywords: GABAA receptors, GABAA receptor isoforms, Carisoprodol, muscle
relaxant, drug abuse

ABSTRACT
ASSESSMENT OF MOLECULAR ACTION OF DIRECT GATING AND
ALLOSTERIC MODULATORY EFFECTS OF CARISOPRODOL (SOMA®) ON
GABAA RECEPTORS
Manoj Kumar, B.Pharm.
Carisoprodol is a centrally acting skeletal muscle relaxant frequently prescribed for
the treatment of acute musculoskeletal conditions. Recreational use of carisoprodol is an
increasing problem. Recent reports highlight the dangers involved in carisoprodol abuse,
including severe withdrawal leading to seizures and death. Indeed, carisoprodol has been
placed into schedule IV drug at federal level effective January 11, 2012 considering its
alarming abuse rate. Until recently, it was widely accepted that the sedative effects of
carisoprodol were due predominantly to its metabolite, meprobamate. Our lab recently
concluded, that carisoprodol itself, at low concentrations allosterically modulates and at
higher concentrations directly activates γ-aminobutyric acid, type A receptors (GABAARs),
the predominant inhibitory neurotransmitter receptor in mammalian brain. This may underlie
the capacity of carisoprodol to enhance the sedative effects of CNS depressants, contributing
to its potential for abuse.
GABAA receptors are member of the cys-loop receptor family that are heteropentameric ligand gated chloride ion channels and play a critical role in mediating fast
inhibition in the brain. A diverse number of GABAAR subunits as well as their isoforms have
been identified including α (1-6), β (1-3), γ (1-3), ρ, δ, ε and θ. αβγ and αβδ receptor (2:2:1
stoichiometry) isoforms are the predominant GABAARs in the CNS. αβγ GABAARs
generally located within the synapses mediating GABAergic phasic inhibition, whereas αβδ
receptors are preferentially targeted to extrasynaptic membranes inducing tonic inhibition.
Each GABAAR subunit is composed of a large extracellular N terminus, four transmembrane
helices (TM1–TM4), one extracellular TM2–TM3 loop, two intracellular loops (TM1–TM2
and TM3–TM4), and an extracellular C terminus. TM2 from each subunit line the pore of
the channel and gate. We hypothesized that carisoprodol modulates GABAARs in a subunitdependent manner, possibly through a novel site of action, with different amino acid domains
contributing to direct gating and allosteric modulatory actions of carisoprodol. We used
HEK293 cells, stably and transiently expressing desired GABAA receptor and took
advantage of whole cell patch clamp electrophysiology and site directed mutagenesis
techniques to address following specific aims: 1) To identify subunit-dependent influence on
direct gating and allosteric enhancement effects of carisoprodol on GABAARs; 2) To identify
GABAA receptor subunit domains that confer carisoprodol sensitivity.
Our studies demonstrate direct gating and allosteric modulatory effects of
carisoprodol are GABAA receptor isoforms dependent. Specifically, carisoprodol is most
efficacious on α1 containing receptors for allosteric modulatory action and least efficacious
on α3 containing receptors for direct gating action. Also, presence or absence of γ subunit in
ii

GABAAR does not affect carisoprodol direct gating and allosteric modulatory efficacy.
Regarding δ containing extrasynaptic receptors, carisoprodol is more efficacious than GABA
and potentiated the maximal GABA-gated currents like barbiturates and general anesthetics.
Mutagenesis studies showed, transmembrane 4 domains of α subunit are involved in direct
gating action of carisoprodol but not in allosteric modulatory action. Mutation of valine at
440 TM4 domain of α3 subunit to corresponding α1 subunit residue leucine 415 significantly
increased the direct gating efficacy of carisoprodol without affecting allosteric modulation
properties. In corresponding reverse mutation experiments, mutation of α1 subunit residue
leucine 415 to valine 440 residue of α3 subunit significantly reduced direct gating efficacy
of carisoprodol but not allosteric effects. In physicochemical analysis of TM4 415 residue,
polarity and volume of amino acid influenced the direct gating efficacy of carisoprodol.
Taken together, our data indicate that carisoprodol interacts with distinct sites to allosterically
modulate and directly gate GABAA receptors. Also, the pharmacological profile of
carisoprodol at GABAA receptors coincide with its therapeutic effects, and carisoprodol’s
subunit-dependence property may underlie its potential for abuse.
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CHAPTER I
INTRODUCTION

Carisoprodol (CSP) is a centrally acting muscle relaxant, frequently prescribed to
relieve skeletal muscle spasms and associated pain (Toth and Urtis, 2004). Recent evidence
confirms carisoprodol abuse leads to several adverse effects, such as psychomotor
impairment and severe withdrawal that may predispose to hallucinations, seizures and death
(Bramness et al., 2004; Fass, 2010; Zacny and Gutierrez, 2011; Zacny et al., 2012).
Carisoprodol abuse has increased rapidly in recent years. Recreational users abuse
carisoprodol for its muscle relaxing, anxiolytic and sedating effects, and often mix it with
other CNS depressants to enhance its sedative or euphoric effects (Hardon and Ihsan, 2014).
The Drug Enforcement Agency (DEA) has reported cases of carisoprodol intoxication are
increasing. Seizures induced by carisoprodol misuse increased from 3,988 in 2008 to more
than 5000 in 2010, higher than other abused drugs including like lorazepam and
methylphenidate (Witenko et al., 2014). Increasing popularity of carisoprodol among high
school students is also a topic of concern. According to Monitoring the Future National
Survey on Drug Use (2009), annual non-medical use of carisoprodol among all high school
seniors was 1.3% and 1.4% in 2007 and 2008, respectively (Reeves et al., 2012). These
numbers are higher than other prescription drugs that are abused like chlordiazepoxide
(0.2%) and lorazepam (0.4%) and comparable to clonazepam (1.3%) (Reeves et al., 2012).
Considering the danger posed by carisoprodol and its increasing abuse rate, an understanding
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of its mechanism of action is of interest. Its physiological effects have generally been
attributed to actions of its primary metabolite, meprobamate (Reeves et al., 1999b) on GABA
type A receptors (GABAARs), the predominant inhibitory neurotransmitter receptor in the
brain (Sigel and Steinmann, 2012). However, it is now known that carisoprodol can directly
gate and allosterically modulate the GABAAR, likely through a novel site(s) of action
(Gonzalez et al., 2009b), and thus many actions may be attributable to the parent drug
carisoprodol. In this overview, the current understanding with regard to the abuse potential
of carisoprodol, therapeutic and abuse-related actions of this drug, and possible molecular
actions that underlie these effects is discussed.

Clinical Use of Carisoprodol
Carisoprodol was first approved in 1959 by the Food and Drug Administration
(FDA) for clinical use as a skeletal muscle relaxant (Fass, 2010). It is/has been marketed in
the United States under the brand name Soma, Soridol and Rela in the United States (Littrell
et al., 1993a), Carisoma in the United Kingdom, and under the names Sonoma, Somadril,
Somacid, Scutamil C, Relacton-C, Mio Relax, and Relaxibys in other countries (Reeves et
al., 2012). Carisoprodol is commonly prescribed for acute musculoskeletal spasm and
associated pain in adults. The analgesic, muscle relaxant and sedative effects of carisoprodol
are the basis for its use in the alleviation of lower back pain and in the short-term treatment
of painful, acute musculoskeletal conditions (Toth and Urtis, 2004). Like other muscle
relaxants, carisoprodol is often prescribed as an adjunct to rest or physical therapy and is also
2

available in preparations with other analgesics such as aspirin or codeine (Soma® Compound
or Soma® Compound with codeine) (2004). The onset of action is rapid and effects last for
4-6 hours (Littrell et al., 1993a). It is available in 250 mg and 350 mg tablets, and is
administered 3-4 times a day for a maximum duration of 2-3 weeks. Carisoprodol was the
2nd most prescribed muscle relaxant in the US in 2000, accounting for 21% of all skeletal
muscle relaxant prescriptions. Together with cyclobenzaprine and metaxalone, these three
drugs accounted for 45% of all skeletal muscle relaxant prescriptions dispensed in 2003 and
2004 (Luo et al., 2004; Toth and Urtis, 2004). A market intelligence corporation, IMS
Health, reported 10.6 million prescriptions were dispensed in 2008 alone. The most common
side effects of carisoprodol when taken medicinally are drowsiness, dizziness, and headaches
(Bramness et al., 2007a). Other side effects include nausea, vomiting, hypotension,
tachycardia, ataxia, vertigo, tremors and seizures. Adverse effects are generally observed
after high dose administration or sudden cessation. Toxic doses of carisoprodol elicit
agitation, myoclonus and bizarre movements (Bramness et al., 2005a; Roth et al., 1998).

Pharmacokinetics and Metabolism
Carisoprodol is a white crystalline powder with mild characteristic odor and a bitter
taste. It is a racemic mixture of two stereoisomers, (RS)-2-{[(aminocarbonyl)oxy]methyl}2-methylpentyl isopropylcarbamate. Its molecular weight is 260.33 and its octanol\water
partition coefficient is 2.36. Carisoprodol solubility is independent of pH. It is freely soluble
in organic solvents DMSO, chloroform, acetone and alcohol and moderately soluble in water
3

(30 mg/100 mL at 25 oC (Littrell et al., 1993a). The structure of carisoprodol is closely related
to meprobamate, differing only by a hydrogen atom substituting for the isopropyl group on
one of the carbamyl nitrogens (Figure 1). Carisoprodol’s structure is also closely related to
felbamate, an anti-epileptic drug used to treat partial and generalized seizures. However, later
reports of liver failure and aplastic anemia limits its usage to severe refractory seizures. The
CYP2C19 genotype influences the pharmacokinetics of carisoprodol, and thus carisoprodol
and meprobamate blood concentrations. EMs and IMs (extreme and intermediate
metabolizers) metabolize carisoprodol with a half-life of 1.5 hours (Dalen et al., 1996; Olsen
et al., 1994). Around 2-3% of Caucasians are PMs (poor metabolizers); they eliminate
carisoprodol with a half-life of more than 6 hours and generate meprobamate to a small extent
(Tamminga et al., 2001). Carriers of deficient CYP2C19 alleles accumulate higher
concentrations of carisoprodol that may lead to intoxication, while potentially high levels of
the active metabolite meprobamate can accumulate in CYP2C19*17 carriers. However,
CYP2C19 genetics alone do not appear to play a significant role in carisoprodol-related
mortality (Hoiseth et al., 2012). Instead, interaction with other drugs likely plays a key role
in carisoprodol-related fatalities (McIntyre et al., 2012).

Postmortem evaluation of

carisoprodol concentration in blood and liver has shown carisoprodol concentrations as low
as 15 mg\L in blood and 50mg\kg in liver can be fatal in the presence of other
sedative/hypnotics like alcohol, diazepam, alprazolam and temazapam (McIntyre et al.,
2012).

4

Age, sex and co-administration of other drugs that interact with CYP2C19 enzyme
also affect carisoprodol metabolism and thus blood concentrations (Tse et al., 2014). A
retrospective study conducted on 14,965 subjects assessed effects of age, sex and drugs that
inhibit CYP2C19 enzymes (esomeprazole, fluoxetine or omeprazole). Metabolic rates were
twice as high in young subjects compared to elderly, and were approximately 20% higher in
females than males (Tse et al., 2014). Also, esomeprazole and fluoxetine, but not
omeprazole, significantly decreased the metabolic rate of carisoprodol. Use of oral
contraceptives inhibits the metabolism of carisoprodol in a CYP2C19 genotype-dependent
manner; IMs using oral contraceptives accumulate more carisoprodol than EMs using them
(Bramness et al., 2005b). As more than 25% of women aged 20-40 use oral contraceptives
(Ronning, 2001), it is important for clinicians to be aware of the potential effects on
carisoprodol concentration in those taking oral contraceptives.

5

Figure I-1. Metabolism of carisoprodol via cytochrome CYP2C19 enzyme. Carisoprodol
is metabolized by cytochrome CYP2C19 enzyme via N-dealkylation of its isopropyl group
to form active metabolite meprobamate. Carisoprodol also metabolized to an inactive
metabolite, hydroxyl- carisoprodol, but to a very small extent by an unknown enzyme.
Meprobamate and hydroxyl- carisoprodol are further metabolized to hydroxyl-meprobamate
and conjugate and excreted by in urine.
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Abuse and Withdrawal Syndrome
Carisoprodol was developed as an analog of meprobamate, promoted as having less
abuse liability and better muscle-relaxing properties (Nebhinani et al., 2013). An early report
suggested carisoprodol did not substitute for morphine or barbiturate and did not produce
morphine- or barbiturate-like intoxication or withdrawal symptoms, and it was thus
concluded carisoprodol does not pose abuse liability (Littrell et al., 1993a). However, more
recent reports confirmed its abuse potential as well as subjective and psychological
impairment and severe withdrawal syndrome that may predispose to seizures and even death
(Fass, 2010; Gonzalez et al., 2009a; McIntyre et al., 2012; Ni et al., 2007; Reeves and Burke,
2010; Reeves et al., 2012; Zacny et al., 2012). The American Association of Poison Control
Centers reported 2632 cases of intentional carisoprodol ingestion requiring medical attention
in 2008 (Bronstein et al., 2009).
Studies conducted in healthy individuals showed a single supra-therapeutic 700 mg
dose of carisoprodol produced both subjective and psychomotor impairments, whereas a
single therapeutic dose (350 mg) produced mainly psychomotor impairments and minimum
subjective impairments (Zacny et al., 2011). Administration of 10 mg oxycodone within 1
hour of 350 mg carisoprodol further affected the psychomotor impairments (Zacny et al.,
2012). A study conducted in northern India also assessed dose-dependent effects of
carisoprodol (Nebhinani et al., 2013). In that study, consumption of 1-3 tablets produced
feelings of well-being and an energetic state, consumption of 4–10 tablets produced
psychomotor excitement, cheerfulness, increased socialization and self-confidence, while
8

consumption of a one-time dose of 10 tablets produced an acute organic brain syndrome-like
state with disorientation and partial amnesia of the events occurring during intake. In a study
conducted by Reeves and Burke (Reeves and Burke, 2010), subjects consuming 12-30 tablets
a day alone or in combination with other drugs like tramadol, benzodiazepines or alcohol
reported euphoria and hallucinations. Misuse of carisoprodol has also been associated with
suicide attempts (Bailey and Briggs, 2002).
In patients taking prescribed carisoprodol for extended use, the desire to continue its
use is strong. Owens et al (Owens et al., 2007) found in approximately 80% of reported cases,
patients continued to purchase carisoprodol even after their insurance declined to cover the
bills. A survey of 40 individuals who had been taking carisoprodol for more than 3 months
showed half of them had a history of drug abuse. Out of those 20 people, 40% admitted to
taking more than the prescribed dose, 30% admitted taking for effects other than low back
pain, 10% admitted taking to stimulate effects of other drugs being abused, and 5% admitted
taking to counter the effects of other drugs (Reeves et al., 1999b). Collectively, the evidence
suggesting carisoprodol has addictive properties and abuse potential is high. Of concern is
the fact that physician awareness of the potential dangers of carisoprodol may be inadequate.
Whereas 95 out of 100 physicians reported knowing meprobamate is a controlled substance,
only 18 were aware that carisoprodol is metabolized to meprobamate (Reeves et al., 1999b).
Now that carisoprodol is also scheduled, the recognition of dangers associated with its misuse
should be improved.

9

Carisoprodol is passed to nursing infants during breastfeeding. Serum concentrations
of carisoprodol and meprobamate were measured from a nursing mother who took 3 times
the normal dose of carisoprodol per day for severe back spasms before and after
uncomplicated delivery, and during the first month of breast feeding (Briggs et al., 2008).
Significant amounts of carisoprodol and meprobamate were found in both the breast milk
and the infant’s serum, but no developmental toxicity was observed. Mild sedation in the
baby while breast feeding was reported, however no signs of withdrawal were observed after
feeding was stopped.
Carisoprodol abuse has increased rapidly in recent years. Low cost and easy
accessibility compared to other illegal drugs make it an ideal choice for substance abusers.
Abusers often combine carisoprodol with other psychoactive drugs to augment or alter their
effects. For example, it may be combined with alcohol or benzodiazepines to increase their
sedative effects, with cocaine to attenuate jitteriness associated with its use, and with other
drugs to get synergistic relaxation and euphoria (Reeves and Burke, 2010; Reeves and
Liberto, 2001). Individuals may substitute carisoprodol for opiates or benzodiazepines if
these drugs are not accessible (Reeves et al., 1999a). As per the National Survey on Drug
Use and Health in 2009, an estimated 2.9 million people in the United States admitted
lifetime consumption of carisoprodol for non-medical purposes. In 2008, the National
Forensic Laboratory information system reported carisoprodol as 1 of the 25 most frequently
abused drugs (Fass, 2010). In 1996, the DEA proposed scheduling of carisoprodol, but the
FDA and drug advisory committee did not take this action, feeling the evidence regarding
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abuse potential of carisoprodol was insufficient (Fass, 2010). Following additional hearings
on the possible scheduling of carisoprodol in 2010, carisoprodol was placed in schedule IV
of the Controlled Substance Act of 1970 effective January 11, 2012 (see ref: Schedule of
control substances). Since the earlier review, a better understanding of the potential
mechanism underlying its actions had been developed, and abuse of carisoprodol had risen
significantly.

For example, in 2009, out of roughly 50,000 emergency department visits

related to abuse of musculoskeletal relaxants,

30,000 visits were due to misuse of

carisoprodol; this is double the number of visits related to carisoprodol abuse reported just
five years earlier (Reeves et al., 2012). Considering the subjective, psychomotor impairment
and CNS depressant effects of carisoprodol, it is not surprising that carisoprodol use
increases risk of traffic accidents and accidents while operating heavy machine (Zacny et al.,
2011). Indeed, carisoprodol and meprobamate have been ranked 7th out of the top 10 classes
of drugs associated with driving under the influence of drugs, and this activity may in fact
result in a charge of driving while intoxicated (Bramness et al., 2007b).
Carisoprodol abuse is not only an issue in the United States; its abuse has been
documented in many other countries (Bramness et al., 2007a; Bramness et al., 2007b; Hardon
and Ihsan, 2014; Nebhinani et al., 2013). In 2007, Norway scheduled Carisoprodol as class
“A” drug, which is the highest scheduling level in Norway and a category that includes
narcotics and hypnotics (Hoiseth et al., 2009). Recently, the Committee for Medicinal
Products for Human Use concluded the abuse potential associated with carisoprodol
outweighs its benefits as a therapeutic drug; carisoprodol was removed from the market by
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the European Medicines Agency in 2008 and is only available to those for whom there are
no other alternatives (Hoiseth et al., 2009). In South Sulawesi, sex workers spend nearly all
their earnings to buy carisoprodol (Hardon and Ihsan, 2014). They take up to 10 pills a day,
often along with alcohol and other psychoactive prescription drugs, to make their work
palatable. Carisoprodol has become a cross-border problem as well. Several thousands of
pills can easily be purchased at a time in Mexico to be smuggled over to the United States
and sold to teenagers (Davis, 2009). Correspondingly, the Los Angeles police department
reported carisoprodol is one of the prescribed drugs they encounter most frequently at the
US-Mexico border crossing (Reeves and Burke, 2010).
A significant problem with carisoprodol is that tolerance to its effects develops
rapidly, and increased consumption of tablets often follows. Subsequent abrupt cessation
results in withdrawal syndrome (Gatch et al., 2012). Abrupt cessation of carisoprodol
administration in humans (100 mg/kg/day, 5 times the normal daily dosage) results in
insomnia, abdominal cramps, headache, chills and nausea (46). Hallucinations, delusions,
tremors, seizures and even death have also been reported (Ni et al., 2007; Reeves et al., 2004;
Reeves and Burke, 2010). Prisoners in Norway who had been taking 700 - 2100 mg/day of
carisoprodol for at least 9 months showed withdrawal symptoms including insomnia,
anxiety, irritability and muscular pain upon sudden discontinuation of drug intake (Wyller et
al., 1991) . Whereas withdrawal symptoms are generally associated with cessation of large
doses of carisoprodol, they have been observed with cessation of as few as 4 to 8 tablets of
carisoprodol per day (Reeves et al., 1997). Whereas toxic and withdrawal symptoms have a
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notable GABAergic component (below), other systems may be affected. Bramness et al
(Bramness et al., 2005a) reported 4 cases where subject had consumed up to 65 pills of
carisoprodol alone or along with other sedative/hypnotics; these subjects showed
characteristic effects that might be associated with serotonergic activation, such as
tachycardia, hypertension, involuntary, robot-like, choreiform movements, tremors and
shivering (Bramness et al., 2004; Roth et al., 1998). In that study, however, signs and
symptoms included in the classification of serotonergic syndrome were nonspecific; because
a complete drug screening was not performed, one cannot rule out the possibility that other
drugs present were eliciting the serotonergic effects. Currently, a suitable and efficient
treatment for carisoprodol intoxication and withdrawal is not available. Withdrawal
syndromes are treated with barbiturates and benzodiazepines to suppress anxiety and
agitation (Reeves et al., 2007). Treating carisoprodol overdose is more complicated because
of the presence of serotonergic-like symptoms noted above. A benzodiazepine antagonist is
generally given in cases of carisoprodol intoxication, but considering carisoprodol does not
act at the benzodiazepine site (below), this is not an entirely appropriate approach.

Pharmacology of Carisoprodol
Carisoprodol mediates its effects centrally rather than through direct skeletal muscle
relaxation (Gonzalez et al., 2009b). Inhibition of inter-neuronal transmission in the
descending reticular formation and spinal cord is one of the mechanisms proposed for its
muscle relaxant properties. Whereas the precise mechanism of action of carisoprodol is not
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fully understood, it has been thought that carisoprodol exerts its effects via its metabolite,
meprobamate. Meprobamate is a sedative-hypnotic that was commonly used in the treatment
of anxiety. It is currently classified as a schedule IV controlled substance at the federal level,
with abuse potential comparable to that of benzodiazepines (Mounier et al., 2012; Roache
and Griffiths, 1987). Meprobamate was introduced in 1955 under the brand names Miltown
and Equnil, but within a few years was replaced by benzodiazepines because of high abuse
liability (Reeves et al., 2012). Although the central mechanism of action of meprobamate
has also not been fully elucidated, GABAA receptors are a key target. Meprobamate
allosterically potentiates GABAA receptors and directly gates the receptor at millimolar
concentrations (Rho et al., 1997). Meprobamate intoxication causes cardiogenic
hypotension, CNS depression, flaccid muscles and loss of tendon reflexes (Allen et al.,
1977). As noted, it was assumed therapeutic effects and abuse potential of carisoprodol are
due to its metabolism to meprobamate (Littrell et al., 1993b). Following a single 700 mg
dose of carisoprodol, serum levels of meprobamate surpass those of carisoprodol in 2.5
hours, and approximately 90% of carisoprodol is metabolized to meprobamate in 6 hours
(Olsen et al., 1994). Despite the likely contribution of meprobamate to the therapeutic and
adverse effects of carisoprodol, the pharmacological and physiological effects of
carisoprodol are somewhat distinct, suggesting carisoprodol has its own actions (Gonzalez
et al., 2009a). For example, supratherapeutic doses of meprobamate mainly result in CNS
depressant effects such as dizziness, drowsiness, ataxia, tremors, blurred vision and
headache, whereas agitation and bizarre movements occur with toxic levels of carisoprodol.
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Moreover, signs of toxicity are observed within 30 minutes of overdose of carisoprodol (t ½
1.5 hours), before it is metabolized to meprobamate (t ½ 11 hours) (Littrell et al., 1993a).
Gonzalez et al., using whole cell patch electrophysiology in HEK cells, showed
carisoprodol itself allosterically modulates and directly activates GABAARs (GABA type A
receptors) (Gonzalez et al., 2009b). Carisoprodol inhibits the receptor at high concentration,
eliciting rebound currents upon termination of drug application, as observed with
barbiturates. In vivo studies showed maximal depression of motor activity was observed
within 10 minutes of carisoprodol administration, a timeframe inconsistent with effects being
due to conversion to meprobamate (Gonzalez et al., 2009b). In addition, in rats trained to
discriminate

carisoprodol

from

saline,

the

GABAergic

ligands

pentobarbital,

chlordiazepoxide and meprobamate substituted for carisoprodol. These results suggest
GABAA receptors as potential targets of carisoprodol, and demonstrate its capacity to
enhance the sedative effects of CNS depressants, contributing to its potential for abuse.
Discriminative stimulus effects of carisoprodol were blocked by the barbiturate antagonist
bemegride, but not by the benzodiazepine antagonist flumazenil. Similarly, carisoprodolgated currents were blocked by bemegride but not by flumazenil. These results rule out the
involvement of the benzodiazepine binding site in carisoprodol modulation of GABAA
receptors. Recently, Gatch et al. (Gatch et al., 2012) characterized tolerance and dependence
potential in mice. Tolerance (measured as loss of righting reflex) developed quickly, as mice
showed a decrease in the loss of righting reflex following just 4 doses of carisoprodol.
Whereas spontaneous withdrawal symptoms were not produced within 24 hours following
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withdrawal from carisoprodol, precipitated withdrawal signs were observed with
administration of either the benzodiazepine antagonist flumazenil or the barbiturate
antagonist bemegride. Although drug discrimination and electrophysiological studies
suggest possible overlap of the mechanism of action of carisoprodol and barbiturate effects,
site-directed mutagenesis on homomeric ρ1 GABA receptors have shown functional
domains are not equivalent. Specifically, mutation of tryptophan to methionine at position
328 of the ρ1 subunit (ρ1W328M) confers pentobarbital direct gating sensitivity to
insensitive wild type ρ1 GABA receptors, but this mutation does not confer sensitivity to
carisoprodol (Gonzalez et al., 2009b). Thus whereas carisoprodol shares several properties
with barbiturates and a barbiturate antagonist can attenuate some of its effects, the two
molecules interact at distinct sites on the GABAA receptors.

GABAA Receptors
GABA is the major inhibitory neurotransmitter in the vertebrate central nervous
system and in the central and peripheral nervous system of invertebrates (DeLorey and Olsen,
1992). GABA released from GABAergic neurons generate postsynaptic neuronal inhibition
through a variety of membrane bound receptors, GABA(A-C) type receptors (Sigel and
Steinmann, 2012). These GABA receptors can be divided into two categories, ligand-gated
ion channels (GABAA and GABAC receptors) and metabotropic receptors (GABAB receptor)
that are G-protein coupled receptors (Bormann, 2000). GABAA receptors are the most
predominant inhibitory receptor in human CNS and are selective for Cl- ions (DeLorey and
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Olsen, 1992). Influx of chloride ions hyperpolarize the post-synaptic neurons and is essential
for the balance between the neuronal excitatory and inhibitory signaling that is critical for
normal brain function (McBain et al., 2015; Moss and Smart, 2001). Excessive inhibition or
lowered excitation can lead to sedation, hypnosis, sleep, depression and coma whereas
excessive excitation or lowered inhibition can result in anxiety, convulsions, restlessness and
insomnia (Johnston, 2005). Precise symptoms depend upon the exact region of the brain and
nerve cells that are out of balance (Whiting, 2003). Any extreme imbalance can lead to death.
The aim of the therapeutic drugs that target GABAAR is to restore balance between inhibition
and excitation (Rudolph and Mohler, 2006; Rudolph and Mohler, 2014).

Structure of GABAA receptors
GABAA receptors are a member of the cys-loop receptor superfamily, a structural
feature shared by entire superfamily (13 amino acids loop contained by a disulphide bond in
the extracellular N-terminal) (Corringer et al., 2012; daCosta and Baenziger, 2013). Other
members of the superfamily include nicotinic acetylcholine, type 3 5-hyroxytryptamine,
GABAC and glycine receptors. nACh and 5HT3 receptors are selective for cations that
depolarize (excite) the neurons whereas GABAA, GABAC and glycine receptors are selective
for anions that hyperpolarize (inhibit) the neurons (Miller and Smart, 2010). GABAAR are
heteromeric assemblies of five subunits forming a central ion conducting pore (figure I-2)
(Corringer et al., 2012). Multiple GABAAR subunits as well as their isoforms have been
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identified including α(1-6), β(1-3), γ(1-3), ρ, δ, ε and θ (Barnard et al., 1998; Olsen and
Sieghart, 2008).
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Figure I-2. Molecular homology model of GABAA receptor. A, Side view of pentameric
GABAA receptor representing five subunits, dimensions and position of the various domains
of GABAA receptor on the cell membrane; α subunit in red, β subunit in blue and γ subunit
in yellow. B, Top view of pentameric GABAA receptor representing channel pore and its
dimensions from top of the channel pore to channel gate. Created in Dr. Peter Gannett’s lab
with the help of Dr. Robyn Ayscue. Template was made available online by Dr. Bergmann
(Bergmann et al., 2013).
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Each subunit of the GABAAR is composed of a large extracellular N terminus, four
transmembrane helices (TM1–TM4), where TM2 lines the ion channel pore, one extracellular
TM2–TM3 loop, two intracellular loops (TM1–TM2 and TM3–TM4), and an extracellular C
terminus (figure I-3). Considering the diverse number of subunit isoforms, a large number of
GABAAR can be assembled. However, it has been verified that αβγ and αβδ receptor (2:2:1
stoichiometry) isoforms are the predominant GABAARs in the brain (Quirk et al., 1994) with
αβγ GABAARs mainly located within the synapses and αβδ receptors are preferentially
expressed at extra- or perisynaptic membranes (figure I-4) (Belelli et al., 2009). While
synaptic GABAA receptors exhibit phasic inhibition, extra-synaptic GABAA receptors exhibit
tonic inhibition, persistently activated by low ambient GABA levels present in the extracellular space spilled from synaptic region (Farrant and Nusser, 2005; Glykys and Mody,
2007; Herd et al., 2009). Extra-synaptic GABAA receptors have low efficacy but high affinity
for GABA compared to other ligands such that GABA is considered partial agonist at these
receptors (Bianchi and Macdonald, 2003). Single channel studies have shown αβδ receptors
display brief openings whereas αβγ receptors exhibit burst openings with longer open duration
(Akk et al., 2004; Feng et al., 2004; Wohlfarth et al., 2002). Synaptic receptors that respond
to millimolar concentrations of GABA exhibit fast inhibitory postsynaptic potentials (IPSPs),
whereas extra-synaptic receptors which respond to micromolar concentrations of GABA
spilled in the extra-cellular space consistently exhibit slower IPSPs (Belelli et al., 2009).
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Figure I-3. Schematic representation of major GABAA receptor isoform and
topological model of a single subunit. A, Side view of a single subunit of GABAA receptor
representing a large extracellular N terminus showing cys-loop, four transmembrane helices
(TM1–TM4), where TM2 lines the ion channel pore (grey), one extracellular TM2–TM3
loop, two intracellular loops (TM1–TM2 and TM3–TM4), and an extracellular C terminus.
B, Top view of GABAA receptor representing position of five subunits in anti-clockwise
(β2:α1:β2:α1:γ2). Positive side of the β2 subunit face negative side of the α1 subunit and
negative side of α1 subunit faces positive side of γ2 subunit. The Transmembrane2 (TM2)
(grey) of each subunit line the channel pore. GABA bind at the interface of α1 and β2
subunits and benzodiazepines (BDZ) at the interface of α1 and γ2 subunit. C, Representation
of binding pocket loops of GABA on GABAA receptors. Principal side on β+ subunit; loop
A, B and C and complementary side on α- subunit; loops D, E and F.
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Figure I-4. Localization of synaptic and extrasynaptic GABAA receptors on
postsynaptic neurons and their properties.
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Ion conduction and mechanism of action
GABAARs are selective for Cl¯ ion with some permeability for bicarbonate anions
(Kaila et al., 1989). However, if the extracellular concentration of Cl¯ decreases due to down
regulation of KCC2 Cl¯ ion transporter, opening of GABAAR channel pore results in efflux
of Cl¯ ions leading to depolarization of the neurons and thus, excitation (Coull et al., 2005).
Equilibrium or reversal potential of Cl¯ ion is close to the resting membrane potential and
thus, GABAARs have the capacity to exhibit a different form of dynamics where a small
change in Cl¯ ion concentration can lead to significant changes in the nature of GABAARmediated transmission (Wright et al. 2011). For example, if equilibrium potential of Cl¯ is
more negative than the resting membrane potential GABAAR activation will result in
membrane hyperpolarization and inhibition. If equilibrium potential of Cl¯ is more positive
than the resting membrane potential stimulating GABAARs activation will result in membrane
depolarization and thus excitation. Excitatory GABAA receptors are well documented in early
development and neuropathic pain because of low extracellular Cl¯ levels (Coull et al., 2005;
Wright et al., 2011).
Binding of a neurotransmitter “GABA” on GABAAR initiates a series of molecular
motions (conformational wave) that begin in the binding pocket, followed by movement in
pre TM1 regions to TM(1-4) helices to open the ion pore, a process called coupling (Miller
and Smart, 2010). Binding of the GABA at the binding pocket or site causes the channel to
adopt a conformational open stable state. GABAA receptors have two binding pockets for
GABA at the interface of α and β subunits in the extracellular domains region. The binding
26

pocket is formed by three amino acid loops (A, B and C) on β+ subunit “principal side” and
three amino acid loops (D, E and F) on α- subunit “complementary side” (figure I-3C)(Ernst
et al., 2003). GABAA receptor extracellular domains also have binding pocket for
benzodiazepines at the interface of α and γ subunits (Ernst et al., 2005). How binding of a
ligand leads to channel opening is not clear yet and many theories have been proposed and
studied. One of the regions suggested to be involved in channel gating is a short extracellular
loop between TM2-TM3 (also called TM2-3 linker) (Thompson et al., 2010). Movement in
TM2-3 linker mediated by extracellular domains, destabilizes the hydrophobic ring in the
channel which displaces from the center of the pore to the space between the inner and outer
rings, ultimately opening the channel (Miyazawa et al., 2003). Also, inherited mutations in
this region have been documented which alters the channel gating without affecting ligand
binding (Campos-Caro et al., 1996; Kusama et al., 1994).
Interestingly, opening of cys-loop receptors or GABAA receptors can occur in the
absence of ligand or GABA as well, but at a very low frequency (Thompson et al., 2010). The
binding of ligand increases the probability of channel opening and maximizes as the number
of bound ligands reaches two. Since rate of channel opening can be quicker than the
dissociation of the ligand, multiple opening states can occur during a single ligand binding
(Burzomato et al., 2004). How efficiently ligand docking at binding pocket initiates channel
opening and stabilize the open states is dependent upon how efficient is the communication
or conformation wave between the extracellular domains to transmembrane domains.
Different ligands have different efficacies on GABAA receptors with varying open probability.
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Full agonists initiate channel opening faster or stabilize the channel opening for a longer
duration compared to partial agonists (Baumann et al., 2003).

Modulation of GABAA receptors
Like other proteins, GABAA receptors are regulated by post-translational
modification. Protein kinases have been identified that phosphorylate specific amino acids
residues of specific GABAA receptor subunits and modulate channel gating, surface stability
and trafficking (Adams et al., 2015; Huson et al., 2007). Apart from this covalent
modification, GABAA receptors are modulated by endogenous and exogenous molecules and
may potentiate or suppress the natural response of GABA (Johnston, 2005). Considering the
importance of GABAA receptors in the central nervous system, several classes of exogenous
drug molecules are used. Examples include benzodiazepines, barbiturates, general
anesthetics, ethanol, the competitive antagonist, biculline and the channel blocker, picrotoxin
(Olsen, 2014). These molecules increase GABA-mediated synaptic inhibition either by
directly activating GABAA receptors (Barbiturates) or, by potentiating the action of GABA
on GABAA receptors (Barbiturates/ Benzodiazepines). This latter action is called positive
modulation and is believed to be involved in molecules acting on allosteric sites on GABA A
receptors remote from the GABA recognition sites (orthosteric sites) (figure I-5). Such
allosteric sites are regarded as good targets for the development of subtype specific drugs
since there is generally greater diversity between receptor subtypes in amino acid sequence at
allosteric sites than at orthosteric sites (Johnston, 1996). Molecules that reduce the action of
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GABA on GABAA receptors are known as negative allosteric modulators (Biculline and
Picrotoxin). Molecules that block the actions of both positive and negative allosteric
modulators are known as neutralizing allosteric modulators (benzodiazepine ‘antagonist’
flumazenil)(Christopoulos, 2002). Neurosteroids (Allopregnanolone and THDOC) are the
most potent positive endogenous modulators of GABAARs (Akk et al., 2009). Neurosteroids
have been found to be involved in various disorders, like depression, anxiety, alcohol abuse,
epilepsy, and neurodegenerative diseases (MacKenzie and Maguire, 2013). It has been shown
that the endocannabinoid (2-arachidonoylglycerol) specifically positively modulates β2
subunit-containing GABAA receptors through a binding site located in TM4 (Ernst et al.,
2005). However, physiological role of this modulation is still not clear.
It is suggested that GABAA receptors are modulated by a large range of molecules
because of the numerous binding cavities present in the transmembrane region of the receptor
for these molecules (Ernst et al., 2005). Besides the GABA-binding site, GABAARs have
binding sites for several clinically important drugs, including anxiolytics, sedative-hypnotics,
muscle relaxants, and anesthetics (Johnston, 1996). GABA binding site is located at the
interface of the α1 and β2 subunits in the extracellular domains, whereas the
pentobarbital/general anesthetics (propofol) binding sites are believed to be positioned in the
water accessible region located between the four TM helices of the receptor (Li et al., 2006).
Moreover, the general anesthetics propofol and etomidate also allosterically modulate and
directly gate GABAARs through single site of action (Bali and Akabas, 2004) whereas distinct
GABAAR sites confer these properties to neurosteroids (Hosie et al., 2006). Subunit
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composition and arrangement determine drug selectivity (Dawson et al., 2005; Rudolph and
Knoflach, 2011). Critical questions are whether the allosteric and direct gating effects of
carisoprodol are mediated via a single or multiple sites and how does it modulate GABAA
receptors.
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Figure I-5. Representation of chloride currents gated by GABAA receptor ligands and
their pharmacological properties. A, Representative traces of GABAAR ligands having
only positive allosteric modulation effect and not direct gating action of their own. B,
Representative traces of GABAAR ligands having both positive allosteric modulation effect
and direct gating action. C, Representative traces of GABAAR ligands having only negative
allosteric modulation effect and not direct gating action of their own.
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Distribution and Physiological or Pharmacological Role of GABAAR Subunits
Approximately 20-30% of the neurons in the CNS are GABAergic (Bormann, 2000).
Despite diversity of GABAA receptor subunit isoforms, approximately 60% of all GABAA
receptors consist of α1β2γ2 configuration and 90% of GABAA receptors contain γ2 subunit
(Fritschy and Mohler, 1995). Approximately 15-20% of GABAA receptors have subunit
combination of α2β3γ2, approximately 10-15% have the α3βxγ2 configurations, and
approximately 5% have the α4βxγ or α4βxδ configurations, less than 5% have the α5βxγ2
configurations and similarly less than 5% have the configuration of α6βnγ2 subunit
combinations (Table 2). It is interesting to note, GABAA receptors with two different α
subunits and without γ or δ subunit have also been verified to express (Benke et al., 2004).
Given that GABA is the major inhibitory neurotransmitter, it is not surprising that
GABA is involved, directly or indirectly, in many disorders of brain function (MacKenzie
and Maguire, 2013; McBain et al., 2015). The major disorders for which GABAA receptors
represent major therapeutic targets include anxiety disorders, cognitive disorders, epilepsies,
mood disorders, schizophrenia and sleep disorders (Johnston, 1996; Rudolph and Mohler,
2006; Rudolph and Mohler, 2014). Functional or physiological role of each GABAA receptor
depends upon both subunit composition and localization of the receptor (Dawson et al.,
2005). Malfunctioning of tonic inhibition via δ expressing extra-synaptic GABAA receptors
has been documented to be involved in neurological disorders like depression (Maguire et al.,
2005), schizophrenia (Maldonado-Aviles et al., 2009) and some forms of epilepsy (Cope et
al., 2009) and thus, extra-synaptic receptors are proving to be target of emerging clinical drugs
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(Brickley and Mody, 2012). Also, potentiation of tonic inhibition by neurosteroids, general
anesthetics, anti-epileptics and sedatives/hypnotics is well verified (Bianchi and Macdonald,
2003; Feng et al., 2004).
An understanding of subunit isoform association with physiologic effects of
GABAergic signaling has also developed over the past several years (Olsen and Sieghart,
2009). In an early study using knock-in technology to study roles of a specific amino acid in
the α1 receptor (Histidine at position 101) (Rowlett et al., 2005; Rudolph et al., 1999), mutant
mice expressing α1(H101R) GABAA receptors showed no sedative and anterograde amnestic
effects of diazepam, and anticonvulsant effects were significantly reduced. Equivalent knockin mutations of the conserved histidine were subsequently studied in α2 and α3 receptors
(Crestani et al., 2001). In α2(H101R) mice, anxiolytic and myorelaxant effects of diazepam
were completely abolished, while sedative effects were present. In α3(H126R) mutant mice,
myorelaxant properties of diazepam were reduced (present at high diazepam doses) while
sedative and anxiolytic properties were intact. These results demonstrated diazepam mediates
its muscle relaxant effects mainly through α2 containing GABAA receptors, and also through
α3 GABAA receptors at high concentrations. A drug selective primarily for α2 -expressing
GABAA receptors would likely have better muscle relaxant properties, less abuse potential
and fewer sedative effects (Rudolph and Knoflach, 2011)
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Table I-1. Localization of GABAA receptor subtypes and their physiological and
pharmacological role. Adapted from (Rudolph and Mohler, 2014).
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α subunit
Isoform

Identified
Pharmacological and Synaptic
or
Configurations Physiological Role
Extrasynaptic

α1
60% of all
GABAARs

122

α2
(15-20)%

232

α3
(10-15)%

32,32

α4
less than
5%

2,3d

α5
less than
5%

32

α6
less than
5%

62,32
62,3d

Sedation, Amnesia,
Anticonvulsant action,
Dependence and
Addiction.
Anxiolysis,
Antihyperanalgesia,
Muscle relaxation and
Cognitive impairment

Synaptic

Anxiolysis,
Muscle relaxation,
Sensorimotor gating
and
Antihyperanalgesia

Synaptic

Synaptic

Memory, Anxiety,
Nociception, Sleep and
Neuropsychiatric
disorder
Sensorimotor gating,
Cognitive impairment,
Muscle relaxation,
Autism, Down
Syndrome and
Schizophrenia

Extrasynaptic

Memory, Anxiety,
Nociception, Sleep
disorder, abdominal
obesity and cortisol
secretion

Synaptic and
Extrasynaptic

Synaptic and
Extrasynaptic

Table I-1
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Mechanism of Addiction of Benzodiazepines
The mesolimbic system is well documented for its involvement in the mechanism of
addiction of opioids, ethanol, psychostimulants and nicotine (Luscher and Ungless, 2006).
These drugs increase dopaminergic transmission in the mesolimbic system, increasing the
levels of dopamine in the nucleus accumbens. With regard to additive property at the GABAA
receptors, the ligand for which we have the most knowledge are the benzodiazepines. Tan et
al. showed α1-containing GABAA receptors are involved in addictive properties of
benzodiazepines, and their activation elicits an increase in nucleus accumbens dopamine
levels (Figure I-6) (Tan et al., 2010). GABAergic neurons in ventral tegmental area (VTA)
specifically express α1-containing GABAA receptors, while dopaminergic neurons
transmitting to nucleus accumbens from VTA express α3-containing GABAA receptors (Fig.
6). Potentiation of α1-containing GABAA receptors on GABAergic neurons by
benzodiazepines inhibits the neuron and decreases the release of GABA at dopaminergic
neuron synapses. This inhibition leads to disinhibition of dopaminergic neurons expressing
α3-containing GABAA receptors, resulting in more release of dopamine at nucleus
accumbens. Theoretically, the effects of benzodiazepines at these two sites would effectively
cancel each other out, and thus have nominal effects on dopamine levels. However, the
actions of benzodiazepines are more predominant on α1-containing receptors (Heikkinen et
al., 2009), thus dopamine levels are increased. A better understanding of the carisoprodol’s
interaction at these key GABAAR isoforms would be very significant in understanding its
addictive effects in addition to its therapeutic actions.
37

Figure I-6. Involvement of GABAA receptors in drug addiction pathways. A,
Dopaminergic and GABAergic pathways of mesolimbic system. GABAergic neurons of
ventral tegmental area (VTA) specifically express α1 containing GABAA receptors whereas
dopaminergic neurons express α3 containing GABAA receptors. Dopaminergic neurons
transmits to nucleus accumbens and release dopamine. All addictive drugs increase the
dopamine levels in nucleus accumbens via mesolimbic pathways. B, Benzodiazepines (BZP)
mechanism of addiction and likely path followed by carisoprodol (CSP). Potentiation of α1
expressing GABAA receptors on GABAergic neurons by benzodiazepines or carisoprodol
(likely) inhibit the postsynaptic potential and decrease the release of GABA at dopaminergic
neuron synapses. Decreased GABA levels at the synapses leads to disinhibition of
dopaminergic neurons and increase the dopamine release at nucleus accumbens. Technically
BZP (or CSP) should cancel its effects via potentiation of α3 containing GABAA receptors on
dopaminergic neurons but BZP’s action is predominant on α1 containing GABAA receptors.
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Objective of the dissertation
In light of the fact that GABAA receptors subunit isoforms influence physiologic
effects like anxiety, sedation, addiction, muscle relaxation and drug tolerance and
carisoprodol’s therapeutic effects, we hypothesize that carisoprodol modulates GABAARs
in a subunit-dependent manner, possibly through a novel site of action, with different
amino acid domains contributing to direct gating and allosteric modulation actions of
carisoprodol. Investigation of GABAAR subunit-dependent effects of carisoprodol and
GABAAR subunit amino acid domains that confer carisoprodol sensitivity would provide
critical information for carisoprodol’s molecular mechanism of action, that would help in
understating the mechanism underlying its abuse potential and muscle relaxing properties and
thus, in the treatment of tolerance and withdrawal symptoms of carisoprodol. If carisoprodol
is highly efficacious on α1 subunit containing GABAA receptors, it may be the underlying
mechanism for its ability in enhancing the sedative effects of CNS depressants and its high
potential for abuse. Moreover, the general anesthetics propofol and etomidate also
allosterically modulate and directly gate GABAARs through a single site of action whereas
distinct GABAAR sites confer these properties to neurosteroids. A critical question is whether
the allosteric and direct gating effects of carisoprodol are mediated via a single or two sites.
The aim of the dissertation was divided in two; 1) to identify subunit-dependent influence
on direct gating and allosteric enhancement effects of carisoprodol on GABAARs and 2)
To identify the GABAARs subunit domains that confer carisoprodol sensitivity. To study
the subunit-dependent effect of carisoprodol, we transfected HEK 293 cells with desired
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receptor configuration and tested for direct activation and allosteric modulation by
carisoprodol and to gain insight into possible critical amino acid domains in GABAAR
subunits, we generated site directed mutants of α1 and α3 subunits and tested carisoprodol
sensitivity for direct and allosteric effects.
The quest to develop GABAergic ligands with better delineation of therapeutic and
adverse actions has begun to show considerable promise in recent years, and a number of
agents with unique subunit-selective profiles are in development for the treatment of anxiety,
sleep disorder, down syndrome, autism, schizophrenia and epilepsy (Dawson et al., 2005;
Rudolph and Mohler, 2014). With regard to muscle relaxants, a drug selective primarily for
α2 -expressing GABAA receptors would likely have less abuse potential and fewer sedative
effects (Rudolph and Knoflach, 2011). Considering the fact that low back pain has been one
of the top five reasons for physician visits in the United States for decades (Witenko et al.,
2014), the need to develop a safe and efficacious agent for this substantial medical need is
clear. The overall aim of the study is to gain insight into molecular action of carisoprodol on
GABAARs that would help us in understanding the mechanism underlie carisoprodol’s abuse,
muscle relaxant properties and in development of a new drug with better muscle relaxing
properties and reduced abuse potential.
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ABSTRACT
Carisoprodol is a widely prescribed muscle relaxant, abuse of which has grown
considerably in recent years. It directly activates and allosterically modulates 122
GABAARs, although the site(s) of action are unknown. To gain insight into the actions of
carisoprodol, subunit-dependent effects of this drug were assessed. Whole-cell patch clamp
recordings were obtained from HEK293 cells expressing 12, 13 or xz2 (where x
= 1-6 and z = 1-3) GABAARs, and in receptors incorporating the d subunit (modeling
extrasynaptic receptors). The ability to directly gate and allosterically potentiate GABAgated currents was observed for all configurations. Presence or absence of the 2 subunit
did not affect the ability of carisoprodol to directly gate or allosterically modulate the
receptor. Presence of the 1 subunit conferred highest efficacy for direct activation relative
to maximum GABA currents, while presence of the 2 subunit conferred highest efficacy
for allosteric modulation of the GABA response. With regard to  subunits, carisoprodol
was most efficacious at enhancing the actions of GABA in receptors incorporating the 1
subunit. The ability to directly gate the receptor was generally comparable regardless of
the  subunit isoform, although receptors incorporating the 3 subunit showed
significantly reduced direct gating efficacy and affinity. In extrasynaptic (13d and
3d) receptors, carisoprodol had greater efficacy than GABA as a direct gating agonist.
In addition, carisoprodol allosterically potentiated both EC20 and saturating GABA
concentrations in these receptors. In assessing voltage-dependence, we found direct gating
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and inhibitory effects were insensitive to membrane voltage, whereas allosteric modulatory
effects were affected by membrane voltage. Our findings demonstrate direct and allosteric
effects of carisoprodol at synaptic and extrasynpatic GABA ARs and that subunit isoform
influences these effects.
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INTRODUCTION
-Aminobutyric acid type A receptors (GABAARs) are ion channel-coupled, multisubunit proteins that serve as the primary mediators of inhibitory neurotransmission in the
adult central nervous system (CNS). Functional receptors are composed of individual
subunits arranged in a pentameric manner. In mammals, the various subunits and their
isoforms have been divided into the following classes: (1-6), (1-3), (1-3), , d, e, ,
and q (Huang et al., 2006). Subunit architecture is highly conserved among GABAARs
with each subunit composed of an extracellular amino-terminal, four transmembrane (TM)
domains, a large intracellular loop, and an extracellular carboxyl-terminal. Subunit
composition determines channel conductance, kinetics, and gating properties of the
receptor (Olsen and Sieghart, 2008). Synaptic GABAARs are responsible for phasic
changes in GABA-mediated post-synaptic inhibition. Extrasynaptic receptors, which
typically incorporate a d subunit (Mortensen et al., 2010), exert a tonic inhibitory influence
on neuronal membrane potential. Given their vital role in inhibitory signaling in the CNS,
GABAARs are the targets of several clinically relevant compounds. These compounds
include benzodiazepines, barbiturates, general and inhalational anesthetics, and certain
centrally-acting muscle relaxants.
Carisoprodol is a centrally-acting muscle relaxant indicated in the alleviation of acute
musculoskeletal conditions (Toth and Urtis, 2004). With a single dose of 350 mg, effects
of carisoprodol begin within 30 minutes of administration and plasma concentrations reach
4-7 g/mL in 2 to 4 hours (Littrell et al., 1993). The dangers associated with carisoprodol
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abuse, such as psychomotor impairment and severe withdrawal that may lead to seizures
and death, are well-documented (Adams et al., 1975; Elder, 1991; Littrell et al., 1993;
Reeves and Parker, 2003; Rust et al., 1993; Zacny et al., 2011, 2012). Precipitated
withdrawal studies in mice have demonstrated tolerance to carisoprodol develops in as few
as four doses (Gatch et al., 2012). In recent years, the ready availability of carisoprodol via
internet pharmacies has led to increased recreational use of carisoprodol. Because of the
increasing misuse of carisoprodol and associated adverse effects, the United States Drug
Enforcement Administration placed carisoprodol into Schedule IV of the Controlled
Substances Act in January 2012.
The illicit effects of carisoprodol are generally attributed to the actions of its primary
metabolite, meprobamate—a federally controlled substance with barbiturate-like activity
at GABAARs (Rho et al., 1997). While conversion to meprobamate likely contributes to
the therapeutic and illicit effects of carisoprodol, the pharmacological and physiological
profiles of carisoprodol are not entirely consistent with that of its metabolite, supporting
the possibility that carisoprodol may have effects independent of meprobamate.
The full spectrum of potential targets of carisoprodol has not been established. Adverse
effects may be associated with serotonergic-like effects (Bramness et al., 2004). In animal
studies, the NMDA receptor antagonist dizocilpine partially substitutes for the
discriminative stimulus effects of carisoprodol (M. Gatch, personal communication).
Considerable evidence implicates the GABAAR in is effects. As noted, the metabolite of
carisoprodol has barbiturate-like effects at GABAARs (Rho et al., 1997). We have
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demonstrated carisoprodol itself allosterically modulates and directly activates human
122 GABAARs, and its actions are not mediated via reported sites of action for
benzodiazepines or barbiturates (Gonzalez et al., 2009b). Although receptors of 122
subunit composition are the prevalent configuration in the brain, a vast array of GABAAR
configurations have been shown to exist throughout the CNS, with each configuration
contributing to specific physiological and pharmacological responses (Olsen and Sieghart,
2008). For example, benzodiazepines mediate sedative and anticonvulsant effects through
α1-containing GABAARs, anxiolytic effects primarily through α2-expressing receptors,
and myorelaxant effects via receptors expressing α3 and α5 subunits (Tan et al, 2010). It
has also been demonstrated that abuse and dependence potential of benzodiazepines and
barbiturates are related to their subunit-selective interactions with GABAARs (Ator, 2005;
Ito et al., 1996; Licata and Rowlett, 2008; Wafford, 2005). Because dependence and
withdrawal symptoms are associated with carisoprodol use, a better understanding of its
molecular mechanism is needed. Thus, we assessed direct and allosteric actions of
carisoprodol in varying configurations of synaptic and extrasynaptic GABAA receptors.
Given the clinical and adverse effects associated with carisoprodol, we hypothesized it
would interact with a number of GABAARs in addition to 122, likely those expressing
α2 and/or 3 and/or 5 subunits. Our results indicate that the actions of carisoprodol are
influenced by subunit isoforms and that direct and allosteric effects are likely mediated via
distinct domains.
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MATERIALS AND METHODS
Cell Culture and Transfection
Both stably- and transiently-expressing GABAA receptors HEK293 cells were used
in the present study. Human embryonic kidney 293 (HEK293) cells were transfected with
human GABAA 1-6; human 1-2; and human 2s (short isoform) cDNA in a 1:1:5 ratio
using TransIT®-293 (Mirus Bio, Madison, WI) and used for recording 24-48 h later. The
2s subunit will be referred to as 2 from this point forward. Human GABAA 1 subunit
cDNA was generously provided by Neil Harrison (Columbia University Medical Center,
New York). In resequencing the 2 subunit that was used in many of these studies, we
detected a mutation (D to N at position 115). We mutated this residue to the native form
(QuikChange® Site-Directed Mutagenesis Kit, Agilent Technologies, Santa Clara, CA),
confirmed the mutation via sequencing, and conducted a number of studies to assess
possible impact on carisoprodol activity. We observed no effect and thus data with that
mutation are included. HEK293 stably expressing human 122 or 222 GABAARs
were also used. A complete description of the preparation and maintenance of these stable
cell lines has been published previously (Hawkinson et al., 1996). For studies assessing
carisoprodol effects in a model of extrasynaptic receptors (rat 13d and 43d subunits)
a transfection ratio of 2:1:0.25 for α:β:δ plasmids was used, as this transfection ratio
reliably results in receptors expressing the native 2α:2β:1δ stoichiometry (Wagoner and
Czajkowski, 2010). The rat GABAA α4 subunit cDNA was purchased from Genescript
(Piscataway, New Jersey). As rat extrasynaptic GABA ARs have been shown to have
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similar physiology and pharmacology to human extrasynaptic GABA ARs (Adkins et al.,
2001; Feng et al., 2004; Feng and Macdonald, 2010; Mortensen et al., 2010), use in these
studies is appropriate. For all studies, cells were plated on glass coverslips coated with
poly-L-lysine in 35-mm culture dishes. Cells were incubated and maintained at 37C in a
humidified incubator with an atmosphere of 5% CO2.

Electrophysiology
Whole-cell patch clamp electrophysiology was used to assess GABA- or
carisoprodol-activated Cl- currents. Except for studies examining voltage-dependence
(below), electrophysiology experiments were conducted at room temperature (22-25C)
with the membrane potential clamped at -60 mV. Patch pipettes of borosilicate glass
(1B150F; World Precision Instruments, Inc., Sarasota, FL) were pulled (Flaming/Brown,
P-87/PC; Sutter Instrument Company, Novato, CA) to a tip resistance of 4–6MΩ. Patch
pipettes were filled with a solution consisting of 140 mM CsCl, 10 mM EGTA-Na+, 10
mM HEPES-Na+, and 4 mM Mg2+-ATP, pH 7.2. Coverslips containing cultured cells were
placed in the recording chamber on the stage of an inverted light microscope and
superfused continuously with an external solution consisting of 125 mM NaCl, 20 mM
HEPES, 3 mM CaCl2, 5.5 mM KCl, 0.8 mM MgCl2, and 10 mM glucose, pH 7.3. Agonistinduced Cl− currents were obtained with an Axopatch 200B amplifier with a rate of 50
samples per second (Molecular Devices, Sunnyvale, CA) equipped with a CV-203BU
headstage. Currents were low-pass filtered at 5 kHz, monitored simultaneously on an
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oscilloscope and a chart recorder (Gould TA240; Gould Instrument Systems Inc.,
Cleveland, OH), and stored on a computer using an on-line data acquisition system
(pCLAMP 6.0; Axon Instruments) for subsequent off-line analysis

Chemicals and solutions
Carisoprodol, pentobarbital, THIP (4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3ol), salts and buffers were purchased from Sigma Aldrich (St. Louis, MO). GABA was
obtained from Acros Organics (New Jersey, US). GABA stock solution (500 mM) was
prepared in de-ionized water. A stock solution (1 or 3M) of carisoprodol and THIP (1M)
was made in DMSO. Final concentrations of DMSO in working solutions were 0.3% or
less, a concentration that does not affect GABA-gated current. Diazepam and furosemide
were utilized from a stock solution prepared in water. All stock solutions were stored at 20C. On experimental days, drug-containing solutions were prepared from stock by serial
dilution into external solution.

Experimental protocol
GABA (with or without carisoprodol) or carisoprodol were applied to each cell by
gravity flow using a Y-shaped tube positioned adjacent to the cell. The modulatory effects
of carisoprodol on GABA-gated currents were assessed using an EC20 gating concentration
of GABA as the control. This gating concentration was selected to ensure there was a
sufficient range to observe the full allosteric potential of carisoprodol. To ensure the gating
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concentration was approximately an EC20, control responses were compared to the
maximal GABA-gated current for each individual cell. Carisoprodol was tested only if the
gating concentration was within the EC15-25 range. Control responses were established by
observing two consecutive agonist-activated currents that varied in amplitude by no more
than ± 10%. In our analyses of the modulatory effects of carisoprodol, peak current
amplitude was defined as the maximum current elicited by carisoprodol. In studies
investigating direct gating effects, carisoprodol-gated currents were normalized to
maximum GABA-mediated current. In recordings where an inhibitory component was
observed (high CSP concentrations), a rebound current was sometimes followed the
inhibitory phase. The channel state(s) from which these openings occur may vary (Feng
et al., 2004; Williams et al., 1997; Wooltorton et al., 1997), and thus peak current amplitude
was taken during the active drug application phase. For αβγ configurations, incorporation
of γ2 subunit was confirmed in 1-, 2-, 3- and 522 GABAARs by demonstration of
sensitivity of GABA (EC50)-gated currents to allosteric potentiation by diazepam (1μM).
Antagonism by furosemide (100μM) was used to confirm expression of 422 and
622 GABAARs. Presence of the δ subunit in α1β3δ and α4β3δ receptors was confirmed
by loss of inhibition by 1 µM Zn2+ on GABA-gated current. After establishing the control
response, effects of the test drugs were determined.
To study the voltage-dependence effect of carisoprodol in GABAA receptors,
122 transfected HEK293 cells were clamped at -60 mV and +60 mV and studied for
carisoprodol direct gating, allosteric modulatory and blocking effects as described above.
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Data Analysis
To ensure equipotent concentrations were used for gating, GABA concentrationresponse data were collected for all synaptic and extrasynaptic GABAARs tested, (Table 1
and 4). From these data, EC20 and saturating GABA concentrations were calculated for
each configuration and used in subsequent investigations of the allosteric and direct effects
of carisoprodol, respectively.
Concentration-response profiles for the positive modulatory actions of carisoprodol were
generated (Origin; OriginLab Corp., Northampton, MA) using the equation I/Imax =
[carisoprodol] n/ ([carisoprodol] n + EC50n), where I is the normalized current amplitude at
a given concentration of carisoprodol, Imax is the maximum current induced by
carisoprodol, EC50 is the half-maximal effective concentration of carisoprodol, and n is the
Hill coefficient. For concentration-response curves illustrating allosteric actions, a
correction was applied to subtract direct gating effects. In some cases, the blocking actions
of carisoprodol became notable at high concentrations; in these instances, curves were
fitted to the data point corresponding to peak effect, and the curve was extrapolated.
All data are presented as mean values ± S.E.M. Statistical significance (p<0.05) between
control and test conditions was determined using Student’s t-test (paired or unpaired) and
one-way analysis of variance. Tukey-Kramer post hoc test for multiple comparisons was
performed as needed.
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RESULTS
Influence of  subunit isoform of carisoprodol-mediated activity of the GABAA
receptor
 subunit influences on direct gating by carisoprodol. Table 1 provides EC50
values for the synaptic GABAA receptors studied in the present investigation.

Both

allosteric (assessed using an EC20 GABA gating concentration) and direct effects of
carisoprodol (1µM – 10 mM) were assessed in x22 GABAA receptors, where x = 
subunit 1-6. Carisoprodol directly gated each of the configurations tested, evoking inward
currents in the absence of GABA (Fig. 1A and 1B). Maximal carisoprodol-gated currents
were of similar magnitude regardless of α subunit, with efficacies ranging from 13-43% of
maximal GABA-gated current (Fig. 1B, Table 2). However, carisoprodol direct gating
potency and efficacy was significantly less at α3-containing receptors compared to other α
isoform receptors (Table 2). As originally reported for 1-containing receptors (Gonzalez
et al., 2009b), attenuation of current amplitude at high concentrations, followed by rebound
current, was consistently observed regardless of the  subunit.
 subunit influences on allosteric modulation by carisoprodol of GABA-gated
current. We also assessed the ability of carisoprodol to allosterically modulate the
response to GABA when  subunits were varied. Carisoprodol positively modulated the
effects of an EC20 concentration of GABA in all configurations tested (Fig. 2A and 2B).
Carisoprodol potency was not significantly influenced by the  subunit isoform (Table 3)
whereas the efficacy of carisoprodol modulation was influenced by the  subunit, being
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greatest in 1-containing receptors (Fig. 2B and Table 3). As observed when evaluating
direct gating effects of carisoprodol, allosteric enhancement began to diminish with higher
concentrations of carisoprodol, and a notable rebound current was observed.
Pharmacologically, the presence of carisoprodol increased the apparent affinity of GABA,
resulting in a significant leftward shift in the GABA concentration-response profile without
increasing maximal GABA current amplitude (Fig. 2E).

Influence of  subunit isoform of carisoprodol-mediated activity of the GABAA
receptor
 subunit influences on direct gating by carisoprodol. As we reported
previously (Gonzalez et al., 2009a), application of carisoprodol to 122 receptors
elicited inward currents in the absence of GABA, with an efficacy approximately 43% of
that observed in response to a saturating concentration of GABA (Fig. 1A). The ability to
directly gate the receptor was also observed in 112 GABAARs. Efficacy in 1containing receptors was significantly greater than that observed in 2-containing receptors
(Fig. 1C and Table 2) and approximated 70% of the magnitude of maximal GABA-gated
current in 112 GABAARs. Potency of carisoprodol’s direct gating effect was similar
in 1- and 2-expressing receptors (Table 2).
 subunit influences on allosteric modulation by carisoprodol of GABA-gated
current. Carisoprodol modulated the GABA-gated currents of 112 GABAARs in a
manner previously described for 122 GABAARs—potentiation in a concentration69

dependent manner accompanied by inhibition and rebound currents at millimolar
concentrations (Fig. 2A). The  subunit isoform affected both potency (33.1 ± 4 M and
88.2 ± 20 M, in 1- and 2-containing receptors, respectively) and efficacy (maximum
efficacy was 225 ± 14.6% of control in 1-containing receptors, compared to 474.7 ±
53.5% in 2-containing receptors) of carisoprodol-mediated potentiation of GABA-gated
currents (Fig. 2C and Table 3). This is in contrast to the pattern observed for the direct
gating effects of carisoprodol, in which carisoprodol was more efficacious at receptors
containing the 1 isoform.

Direct gating and allosteric modulatory effects of carisoprodol do not require the 
subunit
In assessing the influence of the  subunit on actions of carisoprodol, we found
its efficacy as a direct agonist was unchanged with the presence of the  subunit (Fig. 1A
and 1D, Table 2). Peak current amplitude of carisoprodol-evoked currents was 45.9 ±3 %
of the maximum GABA-gated current for 12 receptors, whereas it was 43.6 ± 4.3% for
122 receptors. Consistent with this, we observed the actions of carisoprodol were
comparable regardless of whether the 2short or 2long isoform was expressed (data not
shown).
We also assessed the influence of the γ subunit on allosteric actions of carisoprodol.
Micromolar concentrations of carisoprodol potentiated the GABA-gated currents of 12
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GABAARs in a concentration-dependent manner (Fig. 2A and 2D, Table 2). The patterns
of potentiation and inhibition by carisoprodol at 12 GABAARs were similar to those
observed at 122 GABAARs, shown here (Fig. 1A) and previously using a stable 122
cell line (Gonzalez et al., 2009b). The estimated EC50 for carisoprodol at 12 GABAARs
was 87.4 ± 16.4 M compared to 88.2 ± 20 M for receptors containing the 2 subunit,
with direct gating by carisoprodol likely contributing to maximal current amplitude elicited
by higher concentrations of the drug. Maximum potentiation of control currents occurred
with 1 mM carisoprodol for each configuration (Fig. 1D), with efficacies of 346.7 ± 67.6%
and 474.7 ± 53.5% for 12 and 122 GABAARs, respectively. Thus, the  subunit did
not significantly influence the potency or efficacy of carisoprodol as an allosteric
modulator (Table 2). At millimolar concentrations, rebound currents were observed upon
termination of drug application, and co-application of 3 mM carisoprodol elicited an
inhibitory effect on GABA-gated currents during drug application. Together with the direct
gating studies, these findings demonstrate the  subunit is not essential for carisoprodolmediated regulation of GABAAR function.

Effects of carisoprodol in “extrasynaptic” receptors
δ subunit influences on direct gating by carisoprodol. To assess carisoprodol
mediated-activity in a model of extrasynaptic GABAA receptors, we studied its effects in
HEK293 expressing rat α1 or α4, β3 and δ GABAA receptor subunits. Carisoprodol was
more efficacious than GABA in directly gating α1β3δ and α4β3δ extrasynaptic receptors,
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with the latter receptor having the highest sensitivity to CSP (Fig. 3, Table 4). We also
compared the efficacy of carisoprodol to that of THIP, which has high efficacy at
extrasynaptic GABAA receptors (Belelli et al., 2009; Brickley and Mody, 2012). As
reported by others, we observed that THIP was a super agonist, with THIP-gated currents
being 135.6 ± 7.2 and 153.4 ± 10.7% of the amplitude of currents obtained with saturating
GABA in α1β3δ and α4β3δ receptors, respectively. Carisoprodol was thus roughly 90%
as efficacious as THIP in directly gating α1β3δ and α4β3δ receptors (Fig. 3). Direct gating
efficacy by carisoprodol in rat α1β2, α1β3, and α1β3γ2 configurations was similar,
indicating neither the 2/3 isoforms nor the  subunit significantly affects direct activation
by carisoprodol. Effects in the rat α1β2, α1β3 and α1β3γ2 receptors were also generally
comparable to what we observed across a range of human GABAA receptors (see Fig. 1).
Thus, species differences do not appear to be a significant influence with regard to direct
gating effects of carisoprodol, as has been observed for other GABAergic ligands such as
pentobarbital, neurosteroids, THIP and general anesthetics (Adkins et al., 2001; Feng et
al., 2004; Feng and Macdonald, 2010; Mortensen et al., 2010).
δ subunit influences on allosteric modulation by carisoprodol of GABAgated current. We also determined the ability of carisoprodol to allosterically modulate
GABA-gated current in extrasynaptic receptors. In contrast to what was observed with
direct gating, the δ subunit did not have a significant effect on allosteric modulatory effects
of carisoprodol (Fig. 4). These results also confirm carisoprodol is most efficacious on
receptors expressing β2 compared to β1 or β3 subunits for its allosteric modulatory effects
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(Table 4). Interestingly, like pentobarbital, neurosteroids, and general anesthetics (Feng et
al., 2004; Meera et al., 2009; Wohlfarth et al., 2002), carisoprodol potentiated maximal
GABA currents of α1β3δ and α4β3δ GABAA receptors, but not of α1β3 or α1β3γ2
receptors (Fig. 5). These results demonstrate carisoprodol has distinct gating properties on
extrasynaptic GABAA receptors compared to synaptic receptors.

Effect of membrane voltage on direct gating and allosteric modulatory effects of
carisoprodol
As voltage sensitivity may sometimes provide insight into possible site of action
of a ligand, we determined whether direct gating, allosteric modulatory and/or blocking
actions of carisoprodol are voltage-dependent, by assessing these actions in 122
GABAA receptors with the membrane voltage clamped at -60 mV and +60 mV. GABAgated and CSP-gated current at 0 mV was essentially undetectable, consistent with the
theoretical reversal potential of 0.4 mV, as predicted from the Nernst equation. As reported
by others (O'Toole and Jenkins, 2012), we observed outward rectification in response to
lower concentrations of GABA (current amplitude at +60 mV was 110% of that recorded
at -60 mV), whereas no significant rectification was observed at saturating GABA. To
assess voltage-dependence of the direct gating effects of CSP, we chose a concentration of
1 mM, which elicits a robust current, but nominal apparent inhibition. As shown in Figure
6 (A, B), the direct gating effect of CSP was not impacted by membrane voltage.
Interestingly, allosteric potentiation of GABA currents by carisoprodol was affected by cell
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membrane polarity; in these studies, 100 µM CSP enhanced GABA current to 285.3 ±
17.7% of control at -60 mV, whereas the extend of potentiation was 204.8 ± 5.3% at +60
mV (Fig. 6C, 6D).

To assess voltage-dependence of blocking by carisoprodol, we

compared the decrease in current amplitude in response to 5 mM CSP, compared to 3 mM
CSP, at both -60 and +60 mV. The magnitude of current attenuation with 5 mM CSP was
similar in both cases (Fig. 6E, 6F).
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DISCUSSION
Despite the clinical utility of carisoprodol in treatment of low back pain, its use is
complicated by its abuse potential. Carisoprodol abuse, tolerance, and withdrawal are welldocumented in the literature (Adams et al., 1975; Elder, 1991; Reeves and Parker, 2003;
Rust et al., 1993). This abuse has become particularly apparent in recent years, due in part
to ready access of carisoprodol via internet pharmacies. The abuse liability of carisoprodol
has often been attributed to meprobamate—the primary metabolite of carisoprodol and a
controlled substance at the federal level. Our previous research has demonstrated that
carisoprodol itself, independent of its conversion to meprobamate, acts at GABA ARs in a
manner described for drugs of abuse that act via the GABAergic system (Gonzalez et al.,
2009b). Whereas meprobamate has been federally scheduled for many years, such was not
the case for carisoprodol. Effective January 2012, following extensive review of scientific
research and data on abuse, law enforcement encounters, and other information, the United
States Drug Enforcement Agency placed carisoprodol into Schedule IV of the Controlled
Substances Act (Federal Register, vol 76, no 238, pp. 77330-77360, Dec 12, 2011).
The abuse and dependence potential of many GABAergic drugs are related to their
subunit-selective interactions with GABAARs (Ator, 2005; Ator et al., 2010; Ito et al.,
1996; Licata and Rowlett, 2008; Wafford, 2005). Thus, we assessed whether the actions of
carisoprodol are subunit-dependent, potentially underlying its physiological effects and
abuse liability. The role of the  subunit has been established for several modulators of
GABAAR function. The most prominent example is the benzodiazepine class of drugs,
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which require the presence of a  subunit to potentiate GABA-gated currents (Pritchett et
al., 1989). The  subunit does not play an essential role in mediating the actions of
carisoprodol at GABAARs because the modulatory and agonistic effects of the drug were
not significantly different between 12 and 122 configurations. These findings
support our earlier assertion that carisoprodol does not act at the benzodiazepine site of the
receptor (Gonzalez et al., 2009a) and led us to pursue the  and  subunits as critical
mediators of the actions of carisoprodol.
In the current study, the influence of  subunit isoforms was examined via
comparison of effects elicited from 1-, 2- and 3-containing receptors. Whereas the
actions of GABAergic compounds such as etomidate, loreclezole, and furosemide are
dependent upon incorporation of 2 or 3 subunits (Korpi et al., 2002; Korpi et al., 1995;
Olsen, 2014; Stewart et al., 2013), carisoprodol-mediated effects were observed at 112
GABAARs, suggesting critical domains for carisoprodol activity are located within regions
conserved between the 1 and 2 isoforms. For allosteric modulation, carisoprodol was
significantly more efficacious at 2-containing receptors. Expression of the 2 isoform in
the brain is extensive (Sigel and Steinmann, 2012), suggesting the majority of receptor
configurations are susceptible to modulation by carisoprodol. In contrast, direct activation
by carisoprodol was significantly greater at 1-containing receptors. This disparity
suggests allosteric modulation and direct gating by carisoprodol may be mediated by
distinct sites of the  subunit.
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There has been considerable progress in recent years in understanding the
involvement of specific GABAA receptor  subunits in both desired and adverse
pharmacologic actions (for review, see (Rudolph and Mohler, 2006). 1-expressing
GABAA receptors are critical for the sedative effects of benzodiazepines (McKernan et al.,
2000) whereas 2- and/or 3-expressing receptors underlie their anxiolytic actions (Atack
et al., 2005; Dias et al., 2005). In addition, the efficacy of benzodiazepines at 1containing GABAARs may predict their abuse potential (Ator, 2005; Licata and Rowlett,
2008).

Inhibitory GABAergic interneurons in the ventral tegmental area (VTA)

specifically express α1-containing GABAARs (Tan et al., 2010). Potentiation of α1containing GABAARs on these interneurons causes disinhibition of VTA dopaminergic
neurons, resulting in increased dopamine release in the nucleus accumbens. Addictive
drugs increase dopamine levels in the mesolimbic system (Luscher and Ungless, 2006).
As physical dependence is more likely to develop with drugs that interact with a broader
collection of GABAAR subtypes (Licata and Rowlett, 2008), the high efficacy of
carisoprodol for both direct and allosteric effects on α1-containing receptors, coupled with
its ability to interact with GABAAR subtypes, is consistent with its high abuse potential
(Rudolph and Knoflach, 2011).
The therapeutic goal of carisoprodol use is alleviation of low back pain, which
results from centrally-mediated muscle relaxation. Others have demonstrated muscle
relaxation is associated preferentially with 2- and 3-expressing receptors (Crestani et
al., 2001; Griebel et al., 2003; Licata et al., 2005; Licata et al., 2009).

Although
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carisoprodol did not selectively interact with these subunits, it had notable allosteric
modulatory effects on both 2- and 3-expressing receptors and almost similar potency
for direct activation for α2- containing receptors as compared to most abundant
configuration of human CNS, α1-containing receptors (Olsen and Sieghart, 2008). Taken
together, the pharmacological profile of carisoprodol is consistent with its clinical effects
and its potential for abuse. A molecule that selectively interacts with α2/α3 GABA A
receptor subunits would seem promising as a muscle relaxant with reduced abuse potential
and sedative effects (Rudolph and Knoflach, 2011).
Unlike benzodiazepines, carisoprodol also has the ability to directly gate the
GABAAR. Misuse of agents that directly gate the receptor is more likely to result in death
than those that only allosterically enhance receptor activity, and overdose of carisoprodol
is responsible for a substantial number of both unintentional and intentional deaths (Fass,
2010). We observed that carisoprodol elicited significant and concentration-dependent
direct gating effects at the GABAAR. According to case reports, blood or plasma
concentrations of carisoprodol as low as 140 M have proven to be fatal (McIntyre et al.,
2012; Robertson and Marinetti, 2003). Interestingly, this concentration correlates well to
the onset of direct activation for the majority of receptor subunit complexes tested in the
present study.
These studies are the first to explore subunit-dependent actions of carisoprodol, and
thus little is known about possible domains that are key for its actions. One fundamental
question is whether the site for allosteric and direct gating effects is the same. The general
78

anesthetics propofol and etomidate also both allosterically enhance and directly gate the
receptor, and evidence suggests a single site of action confers both properties (Forman,
2011; Ruesch et al., 2012). In contrast, the ability of neurosteroids to directly gate and
allosterically modulate the receptor is mediated via distinct sites (Hosie et al., 2006). Our
data are most consistent with the contention that the two actions of carisoprodol are
mediated via distinct sites. First, we observed greatest direct gating efficacy in 1expressing receptors, whereas efficacy for allosteric modulation was greatest in 2expressing receptors. Similarly, we observed decreased potency and efficacy for direct
gating capacity in 3-expressing receptors, whereas allosteric effects of those receptors
were similar to other  subunit-expressing receptors.
We also studied the actions of carisoprodol on δ subunit-containing extrasynaptic
GABAA receptors, which exert a tonic inhibitory tone as opposed to the phasic inhibition
characteristic of synaptic receptors (Glykys and Mody, 2007; Herd et al., 2009). It should
also be noted that 522 receptors, in addition to a role at synapses (Serwanski et al.,
2006), are present at extrasynaptic sites and have a prominent role in contributing to tonic
inhibition (Caraiscos et al., 2004; Glykys and Mody, 2006).

The involvement of

extrasynaptic GABAA receptor dysfunction in neurological disorders like depression
(Maguire et al., 2005), schizophrenia (Maldonado-Aviles et al., 2009), and some forms of
epilepsy (Cope et al., 2009) has made these receptors an emerging clinical target (Brickley
and Mody, 2012). As GABA has high affinity but low efficacy at extrasynaptic GABA A
receptors, it is considered a partial agonist at these receptors (Bianchi and Macdonald,
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2003). We found that, as reported for other ligands (Bianchi and Macdonald, 2003),
carisoprodol has higher efficacy at extrasynaptic α1β3δ and 3d receptors than does
GABA, and carisoprodol was about 90% as efficacious as the full agonist THIP.

The

efficacy of general anesthetics and sedative/hypnotics in potentiation of GABA-gated
currents at extrasynaptic α6β2δ GABAA receptors depends upon the ambient GABA
concentration or GABA occupancy of the receptors (Houston et al., 2012). The general
anesthetic propofol and sleep-inducing drug THIP potentiate only when the ambient
GABA levels are low and cease to modulate at saturating GABA. On the other hand, the
neurosteroid THDOC (3α,21-dihydroxy-5α-pregnan-20-one) has stronger potentiating
effects on saturated GABA currents compared to submaximal GABA currents (Houston et
al., 2012; Wohlfarth et al., 2002). We found that carisoprodol potentiated at both subsaturating and saturating GABA concentrations. This is also true for pentobarbital (Feng
et al., 2004). The N-terminal domain of the δ subunit has been shown to be involved in
pentobarbital potentiation of saturated GABA currents of α1β3δ receptors (Feng and
Macdonald, 2010).

The profile of carisoprodol at both synaptic and extrasynaptic

GABAAR is similar to that of barbiturates, although equivalent domains for action at
synaptic receptors are unlikely (Gonzalez et al., 2009b). Whether the N-terminal domains
of the δ subunit that influence pentobarbital potentiation of saturated GABA current also
influence carisoprodol sensitivity remains to be determined.
At high concentrations, carisoprodol also inhibits GABAAR function; this is
evidenced by decreasing current amplitude and/or rebound currents associated with
80

termination of drug application.

A similar phenomenon also exists for barbiturates and

gamma-butyrolactones (Akk et al., 2004; Feng et al., 2004; Rho et al., 1996; Williams et
al., 1997; Wooltorton et al., 1997). This rebound current has been explained as reentry into
an active state following desensitization (Wooltorton et al., 1997), or as relief from ligand
binding to a low affinity inhibitory site, which permits reopening of the channel (Akk et
al., 2004; Feng et al., 2004; Rho et al., 1996; Williams et al., 1997). In the case of
carisoprodol, rebound from block seems most likely. We have reported in abstract form
(Kumar and Dillon, 2014) that in wild type homomeric 3 GABA receptors, which are
spontaneously open, application of carisoprodol by itself blocks the spontaneously open
channels.

In homomeric receptors with introduction of a transmembrane domain 2

mutation (mutation of the 6’ T to F), blockade of the spontaneously open current is
eliminated, and carisoprodol instead activates a significant inward current. Thus rebound
currents following high concentrations of carisoprodol appear to be due to CSP dissociation
from a low affinity inhibitory site. We did not fully quantitate the inhibitory effect, as it
likely play a nominal role in the therapeutic or adverse effects of carisoprodol, and its low
affinity combined with drug solubility issues makes accurate quantitation of it difficult.
We also studied whether the actions of carisoprodol on GABA A receptors display
voltage-dependence.

Neither direct gating nor blocking effects were affected by

transmembrane voltage. However, we found allosteric modulatory effects of carisoprodol
were significantly reduced at + 60 mV compared to -60 mV; a similar effect has been
reported for the general anesthetics etomidate, propofol and isoflurane, (O'Toole and
81

Jenkins, 2012). One might conclude the differential voltage-dependence of direct and
allosteric effects supports the likelihood of two sites for these effects. Whereas collectively
our data do support distinct sites, the differences in voltage-dependence for direct and
allosteric effects do not necessarily lead to this conclusion.

The reduced effect of

carisoprodol at + 60 mV may not relate to voltage per se, but instead is likely related to the
enhanced open probability (Po) of the channel when clamped at positive potentials, as
effects of allosteric potentiators are inversely related to Po (O'Toole and Jenkins, 2012).
With regard to lack of voltage-dependence of the inhibitory effect, one might
conclude a site of action in the channel is unlikely. Whereas the presence of voltagedependence of block is consistent with a site of action in the channel, it is not a requirement
for a channel blocking mechanism. Indeed, the prototypical GABAA blocker, picrotoxin,
does not display voltage-dependence (Newland and Cull-Candy, 1992; Yoon et al, 1993),
and there is a considerable body of evidence that picrotoxin binds in the ion channel (see
Bali and Akabas, 2007, and several references therein). The fact that mutation of the TM2
6’ residue does impact carisoprodol-mediated inhibition (Kumar and Dillon, 2014) is
consistent with a site of action within the channel, but definitive conclusions regarding the
site for inhibitory effects of carisoprodol will require additional study.
The recent scheduling at the federal level of carisoprodol confirms the danger this
drug poses when misused and abused. In the current study, we demonstrated carisoprodol
preferentially interacts with selective GABAAR subunits. The pharmacological profile of
carisoprodol at GABAARs we have identified is consistent with the therapeutic effects of
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the drug, and its subunit-selective actions may underlie its potential for abuse. Moreover,
the complex interactions of carisoprodol suggest it interacts with multiple sites on the
receptor. To our knowledge, no other GABAergic ligand has a subunit-dependent profile
equivalent to that of carisoprodol, suggesting this drug may be acting at a novel site.
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Table II-1. GABA sensitivity of different GABAA receptors subunit configurations.
GABA EC50 values and Hill coefficients were calculated from each receptor configuration
as mean  S.E.M. from n cells.
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Receptor
Configuration

EC50 (M)

Hill
Coefficient

n

12

14.0 ± 1.01

1.32 ± 0.11

4

122

35.5 ± 0.64

1.32 ± 0.03

6

222

48.4 ± 5.71

1.09 ± 0.12

9

322

34.8 ± 2.09

1.04 ± 0.06

8

422

4.48 ± 0.29

1.36 ± 0.11

6

522

2.50 ± 0.20

1.11 ± 0.09

6

622

0.47 ± 0.06

1.02 ± 0.12

8

112

6.6 ± 1.07

1.17 ± 0.09

6

TABLE II-1.
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Table II-2. Comparison of potency and efficacy of carisoprodol as a direct gating
agonist at different GABAA receptor subunit configurations. Carisoprodol EC50 was
determined relative to maximum current elicited by carisoprodol. Carisoprodol efficacy is
normalized to maximum GABA-gated currents. The potency and efficacy of carisoprodol
was significantly less at 3-containing receptors relative to other α- subunit isoforms of
GABAA receptors. Each data point represents the mean ± S.E.M from n cells. Significant
differences compared to 122 receptor are denoted by *, p < 0.05; **, p < 0.01.
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Receptor
Configuration

EC50 (M)

Efficacy (%)

n

12

679.3 ± 24.3

45.9 ± 3.0

9

122

685.5 ± 30.4

42.6 ± 4.3

31

222

829.4 ± 50.2

30.1 ± 1.4

9

322

1867.6 ± 92.4*

13.4 ± 1.4**

29

422

757.7 ± 61.3

37.3 ± 5.0

8

522

834.7 ± 60.3

37.7 ± 3.5

9

622

294.3 ± 28.1

36.8 ± 4.7

12

112

728.8 ± 58.1

69.7 ± 5.4*

12

TABLE II-2.
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Table II-3. Comparison of potency and efficacy of allosteric effects of carisoprodol at
different GABAA receptor subunit configurations. EC50 for allosteric modulation by
carisoprodol was calculated in the presence of GABA (EC20). Efficacy was calculated as
maximum current elicited by carisoprodol plus GABA (EC20) normalized to GABA (EC20)
currents. Carisoprodol was significantly more efficacious at receptors incorporating the 1
subunit compared to receptors expressing any other  subunit isoform. Potency was not
affected by  subunit isoform, but was enhanced in 1 vs. 2 expressing receptors. Each
data point represents the mean ± S.E.M. from n cells. Significant differences compared to
122 receptors are denoted by *, p< 0.05.
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Receptor
Configuration

EC50 (M)

Efficacy (%)

n

12

87.4 ± 16.4

346.7 ± 67.6

3

122

88.2 ± 19.9

474.7 ± 53.5

7

222

64.9 ± 19.1

198.5 ± 9.5*

6

322

63.7 ± 16.5

242.7 ± 35.1*

4

422

72.3 ± 10.1

240.0 ± 16.4*

11

522

90.8 ± 14.7

247.6 ± 23.0*

5

622

79.8 ± 13.8

232.6 ± 26.9*

9

112

33.1 ± 4.0*

225.6 ± 14.6*

6

TABLE II-3
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Table II-4. Comparison of carisoprodol effects on δ subunit-containing extrasynaptic
receptors with synaptic GABAA receptors.

Carisoprodol direct gating EC50 was

determined relative to maximum current elicited by carisoprodol and efficacy is normalized
to maximum GABA gated currents. EC50 for allosteric modulation was calculated in the
presence of GABA (EC20) and efficacy was calculated as maximum current elicited by
carisoprodol plus GABA (EC20) normalized to GABA (EC20) currents. Carisoprodol was
supra-efficacious at δ containing extrasynaptic GABAA receptors for direct gating effects
and significantly more efficacious at synaptic receptors incorporating the β2 subunit for
allosteric modulatory effects. Each data point represents the mean ± S.E.M. from n cells.
Significant differences are denoted by #, p< 0.01 (compared to synaptic receptors); ^, p<
0.05 (compared to α1 extrasynaptic receptor) and **, p< 0.01 (compared to rest of the
receptors studied).
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GABA EC50
Receptor
Configuration

CSP gating

CSP modulation

μM

n

Efficacy

α1β2

1.15 ± 0.08

4

31.5 ± 7.87

400 ± 37.4

6

α1β3

0.67 ± 0.06

6

37.1 ± 3.28

390 ± 48.3

α1β3γ2

04.3 ± 0.68

6

44.8 ± 3.23

α1β3δ

1.37 ± 0.09

9

α4β3δ

0.051 ± 0.03

6

EC50

n

Efficacy

EC50

n

442.2 ± 27.7 **

120 ± 10.5

8

9

234.5 ± 18.9

135 ± 12.8

4

436 ± 73.2

4

200.4 ± 09.5

131 ± 12.4

7

119.8 ± 4.7#

718 ± 36.2

9

241.5 ± 25.1

109 ± 11.4

8

135.6 ± 7.2#

242 ± 38.2^

5

181.5 ± 4.02

92.2 ± 15.1

5

TABLE II-4
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Figure II-1.

Influence of GABAAR subunit isoforms on direct activation by

carisoprodol. A, representative traces demonstrating carisoprodol activates human 122,
322, 112 and 12 GABAARs in a concentration-dependent manner. Carisoprodolactivated currents are presented relative to the maximum current elicited by GABA (100 M
for 12 and 1 mM GABA for 122, 322 and 112). At millimolar concentrations,
rebound currents were observed upon termination of drug application. B, concentrationresponse curves for carisoprodol-mediated currents for human 1-, 2-, 3-, 4-, 5-, and
622 GABAARs. 3- subunit expressing receptors displayed significantly less potency
and efficacy to carisoprodol. Initial peak currents and not rebound currents elicited by
carisoprodol were normalized to maximum GABA mediated currents. C, concentrationresponse curves for carisoprodol-mediated currents recorded from 122 and 112
GABAARs. Carisoprodol was significantly more efficacious at 1-containing receptors. D,
concentration-response curves for carisoprodol-mediated currents recorded from 12 and
122 GABAARs. There were no significant differences between the two configurations at
each concentration tested (p> 0.05). Each data point represents the mean ± S.E.M. of
minimum of eight cells. *, p < 0.05; **, p < 0.01.
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Figure II-2. Influence of GABAAR subunit isoforms on allosteric modulation by
carisoprodol. A, representative traces demonstrating the potentiation of GABA-gated
(EC20) currents from human 122, 322, 112 and 12 GABAARs by carisoprodol.
B, concentration-response curves for the allosteric modulation of GABA-gated currents from
human 1-, 2-, 3-, 4-, 5-, and 622 GABAARs by carisoprodol. Peak current
elicited by carisoprodol plus GABA (EC20) normalized to GABA (EC20) mediated currents.
Carisoprodol was significantly more efficacious at α1-containing receptors. C,
concentration-response curves for the allosteric modulation of GABA-gated currents
recorded from 112 and 122 GABAARs by carisoprodol. Carisoprodol was
significantly more efficacious at 2-containing receptors. D, concentration-response curves
for the allosteric modulation of GABA-gated currents recorded from 12 and 122
GABAARs by carisoprodol. There were no significant differences between the two
configurations at each concentration tested (p> 0.05). E, GABA concentration response in
human α1β2γ2 GABAA receptors in the absence (open square) or presence (filled square) of
100 µM carisoprodol. Carisoprodol significantly decreased the GABA EC50 (from 35.5 ±
0.64 to 8.2 ± 0.26 µM (n = 6 and 4, respectively). The average carisoprodol direct gating
effect at 100 µM (2.8 % of maximal GABA-gated current) was subtracted from the summary
data. Each data point represents the mean ± S.E.M. of minimum of three cells. *, p< 0.05,
***, p<0.001.
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Figure II-3. Direct gating action of carisoprodol on extrasynaptic GABAA receptors.
A, representative traces demonstrating carisoprodol (CSP, 1 or 3 mM) activation of 12,
13 and 13γ2 compared to δ- expressing extrasynaptic 13δ and 43δ GABAARs.
GABA concentrations are saturating at each receptor. At 3 mM and above, the amplitude
of CSP-gated current in 43δ decreases significantly, followed by a rebound current. B,
concentration-response curves for carisoprodol-mediated currents in 13, 13γ2, 12
and extrasynaptic 13δ and 43δ GABAARs. The δ subunit-containing extrasynaptic
GABAARs showed highest efficacy for carisoprodol. C, effect of the super agonist THIP
in 13δ and 43δ GABAARs, compared to GABA. D, summary data demonstrating
carisoprodol’s efficacy on δ- expressing extrasynaptic 13δ and 43δ GABAARs
compared to THIP. Carisoprodol is approximately 90% and 88% efficacious as THIP on
13δ and 43δ GABAARs, respectively. Each data point represents the mean ± S.E.M.
of minimum of four cells. #, p < 0.01.
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Figure II-4. Allosteric modulation of extrasynaptic GABAA receptors by carisoprodol.
A, representative traces demonstrating the potentiation by carisoprodol (300 µM) of GABAgated (EC20) currents in 13, 13γ2 and 12 compared to δ-expressing extrasynaptic
13δ and 43δ GABAARs. B, concentration-response curves showing mean allosteric
carisoprodol modulation of GABA-gated currents in 13, 13γ2, 12 and extrasynaptic
13δ and 43δ GABAARs. GABAARs containing β2 subunits showed highest efficacy
for carisoprodol. Each data point represents the mean ± S.E.M. of a minimum of four cells.
*, p < 0.05; **, p< 0.01.
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Figure II-5. Potentiation of saturating GABA current by sub-gating concentration of
carisoprodol in extrasynaptic GABAA receptors. A, representative traces demonstrating
the potentiation of saturating GABA currents by carisoprodol and pentobarbital in
extrasynaptic 13δ and 43δ GABAARs. B, bar graph summarizing carisoprodol’s
significant potentiation of maximal GABA currents in extrasynaptic 13δ and 43δ
GABAARs, as seen with pentobarbital. This effect was not seen in 13 and 13γ2
GABAARs. Each data point represents the mean ± S.E.M. of a minimum of four cells. **,
p< 0.01.
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Figure II-6. Voltage-dependent effect of carisoprodol actions on GABAA receptors. A,
C and E, representative traces from 122 GABAARs transfected HEK293 cells clamped
at -60 mV and +60 mV for carisoprodol’s direct gating, blocking and allosteric modulatory
effects. B, D and F, bar graph summarizing carisoprodol direct gating, blocking and
allosteric modulatory actions, respectively, at -60 mV and +60 mV. Carisoprodol direct
gating and blocking effects are independent of voltage. However, allosteric potentiation of
GABA currents by carisoprodol (100 µM) was significantly reduced compared to the level
of potentiation observed at -60 mV. Each data point represents the mean ± S.E.M. of
minimum of four cells. *, p< 0.01.
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ABSTRACT
The muscle relaxant carisoprodol (CSP, trade name Soma) has recently been
controlled at the federal level as a Schedule IV drug due to its high abuse potential and
consequences of misuse, such as withdrawal syndrome, delusions, seizures and even death.
Recent work has shown that carisoprodol can directly gate and allosterically modulate the
GABAA receptor. These actions are subunit-dependent; compared to other GABAA
receptors, carisoprodol has nominal direct gating effects in 322 receptors.

Here, using

site-directed-mutagenesis and whole cell patch clamp electrophysiology in transiently
transfected HEK293 cells, we examined the role of GABAA receptor α subunit
transmembrane domain 4 (TM4) amino acids in direct gating and allosteric modulatory
actions of carisoprodol. Mutation of α3 valine at position 440 to leucine (present in the
equivalent position in the α1 subunit) increased the direct gating potency and efficacy of
carisoprodol significantly, without

affecting allosteric modulatory effects. The

corresponding reverse mutation, α1(L415V), decreased carisoprodol direct gating potency
and efficacy. Subsequent assessment of a series of amino acids at α1(415) on carisoprodol
efficacy showed the following rank order: (L = I = T = R > Y > W= C = V > G > S). We
conclude α1(415) of TM4 is involved in the direct gating, but not in allosteric modulatory,
actions of carisoprodol. Also, orientation of alkyl or hydroxyl groups at this position
influence direct gating effects. These findings support the likelihood that direct gating and
allosteric modulatory effects of carisoprodol are mediated via distinct binding sites.
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INTRODUCTION
Carisoprodol (N-isopropyl meprobamate, CSP) is a centrally acting muscle
relaxant frequently prescribed for skeleton muscle pain (Luo et al., 2004; Toth and Urtis,
2004). In recent years, misuse and abuse of carisoprodol has become a significant problem.
Carisoprodol abuse causes psychomotor impairment and severe withdrawal that may
predispose to seizures and death (Bramness et al., 2004; Fass, 2010; Reeves et al., 2012;
Zacny and Gutierrez, 2011; Zacny et al., 2011). Tolerance to carisoprodol develops relatively
fast, facilitating the problems associated with withdrawal (Gatch et al., 2012; Reeves and
Burke, 2010). As per the National Survey on Drug Use and Health in 2009, an estimated 2.9
million people in US admitted that they had consumed carisoprodol for non-medical purpose
(see ref: Drugs and chemical of concerns). Indeed, considering its alarming abuse rate,
effective January of 2012, carisoprodol was scheduled at the federal level (see ref: Schedule
of controlled substances). Considering the danger posed by this drug, there is urgent need for
improved treatment for carisoprodol toxicity, and a novel drug with less abuse potential.
Until recently, it was widely accepted that the sedative and muscle relaxing effects
of carisoprodol were predominantly due to its primary metabolite, meprobamate (Bramness
et al., 2004). More recent work has shown that carisoprodol itself allosterically modulates,
directly activates and blocks γ-Aminobutyric acid, type A (GABAA) receptors in a
concentration-dependent manner (Gonzalez et al., 2009). In vivo studies also support the
fact that carisoprodol itself has significant CNS effects due to interaction with GABAA
receptors (Gonzalez et al., 2009).
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GABAA receptors are member of the cys-loop family of ligand-gated ion channels;
they are hetero-pentameric Cl- channels and play a critical role in mediating fast inhibition
in the brain (Corringer et al., 2012; Sigel and Steinmann, 2012). Multiple GABAA receptor
subunits and corresponding isoforms have been identified, including α (1-6), β (1-3), γ (1-3),
ρ, δ, ε and θ (Olsen and Sieghart, 2008). Each subunit is composed of a large extracellular N
terminus, four transmembrane helices (TM1–TM4), an extracellular TM2–TM3 loop, a large
TM3–TM4 intracellular loop, and an extracellular C terminus (Cockcroft et al., 1995). The
TM2 domains form the pore of the channel (Miyazawa et al., 2003; Xu and Akabas, 1996))
(Fig. 1). In addition to the GABA binding site, GABAA receptors have binding sites for
several clinically important drugs, including anxiolytics, sedative-hypnotics, muscle
relaxants, and anesthetics. The GABA binding site is located at the interface of the α1 and
β2 subunits, and benzodiazepines bind at the interface of α1-γ2 subunits in the extracellular
region (Newell and Czajkowski, 2003; Sigel and Steinmann, 2012) (Fig 1A). Barbiturate and
general anesthetic (propofol, etomidate) binding sites are believed to be positioned in the
water accessible region located between the TM helices of the receptor (Bali and Akabas,
2004; Siegwart et al., 2002; Zeller et al., 2007a). Carisoprodol actions are not mediated via
reported sites of action for benzodiazepines or barbiturates (Gonzalez et al., 2009). While the
general anesthetics propofol and etomidate allosterically modulate and directly gate GABAA
receptors through a single site of action (Siegwart et al., 2002; Stewart et al., 2013), distinct
GABAA receptors sites confer these properties to neurosteroids (Hosie et al., 2006).
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Although not definitive, work to date suggests carisoprodol may mediate its effects via
distinct sites of action (Gonzalez et al., 2009).
Our recent studies with carisoprodol on GABAA receptors have shown the allosteric
modulatory and direct gating properties of carisoprodol are subunit-dependent (Kumar et al.,
2015). Allosteric modulatory actions of carisoprodol are most efficacious at receptors
incorporating the α1 subunit, whereas α3-expressing receptors show minimal direct gating
effects. Characteristics of carisoprodol effects are consistent with it interacting at the
transmembrane domains (Hosie et al., 2006). Aligned amino acid sequences of human α
subunit isoforms (α1-6) revealed that TM1, TM2 and TM3 are fully conserved in all α
subunit isoforms. The TM4 region of α subunit isoforms is also largely conserved; however,
I419, I423 and V440 residues of α3 differ compared to all other α subunit isoforms (Fig. 1C)
(Barnard et al., 1998; Bergmann et al., 2013). We thus explored the extent to which these
residues may contribute to the ability of carisoprodol to directly gate and allosterically
modulate GABAA receptors. We have identified L415 at TM4 of the α1 subunit as being
critically involved in direct gating actions of carisoprodol.
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MATERIAL AND METHODS
Plasmids and site-directed-mutagenesis
Human cDNA plasmids encoding α1, α3, β2 and γ2 GABAA receptor subunits were
used in the present study. Individual and combined mutations in α1 and α3 cDNA plasmids
were created using Stratagene’s Quik Change II ® site-directed-mutagenesis kit (Agilent
Technologies; La Jolla, CA) and were sequenced to confirm mutations at West Virginia
University’s Genomics Core Facility.

Chemicals and solutions
Carisoprodol, pentobarbital, salts and buffers were purchased from Sigma Aldrich
(St. Louis, MO), GABA was obtained from Acros Organics (New Jersey, US). Pentobarbital
and GABA stock solutions (500 mM) were prepared in deionized water. Carisoprodol stock
solution (1 M) was made in DMSO. All stock solutions were stored at -20° C. On the day of
experiment, fresh working drug concentrations were prepared from stock solution by
dissolving in physiological buffer solution (below).

Cell Culture and Transfection
Human embryonic kidney 293 (HEK293) cells were transfected with human cDNA
encoding desired GABAA receptor subunits. To obtain αxβ2γ2 GABAA receptors, HEK293
cells were transfected with human GABAA 1/3 mutant or wild type ; human 2; and human
2s (short isoform) subunit cDNA in a 1:1:5 (0.3μg : 0.3μg : 1.5μg) ratio using poly jet DNA
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in vitro transfection reagent (SigmaGen Laboratories, MD) and used for recording 24-48 h
later. The 2s subunit will be referred to as 2 from this point forward. Human GABAA 1
subunit cDNA was generously provided by Neil Harrison (Columbia University Medical
Center, New York). Cells were plated on glass coverslips coated with poly-L-lysine in 35mm culture dishes and were incubated and maintained at 37C in a humidified incubator with
an atmosphere of 5% CO2.

Whole-cell patch clamp electrophysiology
All experiments were conducted at room temperature (22-25C) with the membrane
potential clamped at -60 mV. Patch pipettes of borosilicate glass (1B150F; World Precision
Instruments, Inc., Sarasota, FL) were pulled (Flaming/Brown, P-87/PC; Sutter Instrument
Company, Novato, CA) to a tip resistance of 4–6 MΩ. Patch pipettes were filled with a
solution consisting of 140 mM CsCl, 10 mM EGTA-Na+, 10 mM HEPES-Na+, and 4 mM
Mg2+-ATP, pH 7.2. Coverslips containing cultured cells were placed in the recording
chamber on the stage of an inverted light microscope and superfused continuously with an
external solution consisting of 125 mM NaCl, 20 mM HEPES, 3 mM CaCl2, 5.5 mM KCl,
0.8 mM MgCl2, and 10 mM glucose, pH 7.4. Agonist-induced Cl− currents were obtained
with an Axopatch 200B amplifier with a rate of 50 samples per second (Molecular Devices,
Sunnyvale, CA) equipped with a CV-203BU head stage. Currents were low-pass filtered at
5 kHz, monitored simultaneously on an oscilloscope and a chart recorder (Gould TA240;
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Gould Instrument Systems Inc., Cleveland, OH), and stored on a computer using an on-line
data acquisition system (pCLAMP 6.0; Axon Instruments) for subsequent off-line analysis.

Experimental Protocol
GABA (with or without carisoprodol) or carisoprodol was prepared in external saline
solution from stock solutions and applied to each cell by gravity flow using a Y-shaped tube
positioned adjacent to the cell. Recordings were obtained from transfected cells only after
establishing that two consecutive GABA EC20-activated currents varied in amplitude by no
more than ± 10%. For studies investigating direct activation, carisoprodol-mediated currents
were normalized to currents elicited by saturating GABA concentrations. Modulatory effects
of carisoprodol on GABA-gated currents were assessed using an EC20 gating concentration
of GABA as the control (individually determined for each mutant and wild type receptor
studied). This gating concentration was selected to ensure there was a sufficient range to
observe the full allosteric potential of carisoprodol. At the initiation of each recorded cell, it
was confirmed that gating concentration was approximately the EC20 (range of EC15 to EC25
accepted for an individual cell). In recordings displaying inhibition followed by a rebound
current after termination of carisoprodol or carisoprodol plus GABA application (Gonzalez
et al., 2009), the maximal current amplitude achieved during active ligand application was
taken as the peak current.
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Data Analysis
Concentration-response profiles for the positive modulatory actions of carisoprodol
were generated (Origin 9.1; OriginLab Corp., Northampton, MA) using the equation I/Imax =
[carisoprodol]n/([carisoprodol]n + EC50n), where I is the normalized current amplitude at a
given concentration of carisoprodol, Imax is the maximum current induced by carisoprodol,
EC50 is the half-maximal effective concentration of carisoprodol, and n is the Hill coefficient.
For concentration-response curves illustrating allosteric actions, a correction was applied to
subtract direct gating effects. In some cases, the blocking actions of carisoprodol became
notable at high concentrations; in these instances, curves were fitted to the data point
corresponding to peak effect, and the curve was extrapolated. All data are presented as mean
values ± S.E. Statistical significance between control and test conditions was determined
using Student’s t-test (paired or unpaired) and one-way analysis of variance. Tukey-Kramer
post hoc test for multiple comparisons was performed as needed. Correlation assessments
were performed using linear fit in origin 9.1.
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RESULTS
Functional characterization of α3 and α1 TM4 mutant GABAA receptors
For this study, an extensive series of mutations (single point or 2-3 residues) in 1 and
3 subunits were evaluated. In all cases, the mutant subunit was expressed with wild type
2 and 2 subunits, and GABA concentration-response profiles were generated to assess
overall receptor function and to establish gating concentrations for allosteric studies. GABA
EC50 for wild type 1 and 3 receptors were both approximately 35 M (Tables 1 and 2).
In general, shifts in GABA EC50 were modest. Mutations in 3 subunits caused a leftward
shift in the GABA concentration-response curve of 1.9- to 4.6-fold (Table 1). Similarly,
mutations in the α1 subunit had either insignificant or modest effects on GABA EC50, with
the maximal effect being a 2.5-fold increase in GABA EC50 relative to wild type α1 receptors
(Table 2). Thus the mutations had minimal effects on fundamental receptor gating.

Mutation of α3 TM4 amino acids to corresponding α1 amino acids increased direct
gating effect of carisoprodol but not allosteric modulatory actions
Consistent with our previous report (Kumar et al., 2015), the ability of carisoprodol
to directly gate 322 receptors was significantly attenuated compared to GABAA receptors
expressing the α1 subunit (Fig. 2B, Tables 1, 2). Maximal current amplitudes generated by 3
mM carisoprodol were 41.8 ± 2.4 % and 8.5 ± 1.1 % of that generated by saturating GABA
in 122 and 322 receptors, respectively. We thus assessed the potential involvement
of three amino acids we identified in TM4 that were unique to the 3 subunit in this
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attenuated direct gating effect. Residues were mutated to the amino acid found at the
equivalent position in the 1 subunit, either alone or in combination. As shown in Figure 2,
all α3 mutants resulted in a gain-of-function effect, significantly increasing direct gating
currents such that current amplitudes in response to 3 mM carisoprodol were not significantly
different from that obtained in wild type 122 receptors (summary values in Table 1).
As carisoprodol also has a diminished allosteric modulatory effect in 322
receptors compared to 122 receptors (Kumar et al., 2015), we also assessed the extent to
which these mutations might increase sensitivity to the allosteric actions of carisorodol.
Interestingly, allosteric modulatory effects of carisoprodol were not affected by mutations.
Whereas carisoprodol enhanced GABA EC20 currents in all mutated receptors, the magnitude
of the effect for each mutant was not significantly different from that observed in 322
receptors, and the allosteric potentiation fell far short of that obtained in 122 receptors
(Fig. 2D and Table 1).

A single mutation of α1 TM4 L415 amino acid to corresponding α3 V440 amino acid
decreased direct gating effect of carisoprodol.
To confirm the involvement of the identified α subunit TM4 residues in direct
gating action of carisoprodol, we mutated α1 TM4 amino acids to the corresponding α3 TM4
three non-identical amino acids (L394I, A398I, and L415V) (Fig. 1) in all possible
combinations of single, double or triple mutation, and assessed direct gating by carisoprodol.
Out of seven mutations generated, each of those containing the L415V mutation caused a
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significant loss of carisoprodol (3 mM) direct gating effect compared to wild type α1expressing receptors, whereas carisoprodol’s effects in those receptors not incorporating the
L415V mutation were not significantly different from wild type (Fig 3A, 3B and Table 2).
These data indicate the leucine residue at position 415 in the α1 subunit has a key role in the
direct gating action of carisoprodol.

Amino acid residue at α1(415) subunit influences carisoprodol direct gating efficacy.
In an attempt to gain additional insight into physicochemical determinants that
influence carisoprodol direct gating capability at the α1(415) position, we generated and
assessed the following series of mutations: α1(L415S), α1(L415G), α1(L415T) α1(L415Y)
α1(L415W), α1(L415I), α1(L415C) and α1(L415R). These residues provide a range of
amino acid side chain properties, including volume, polarity and hydropathy. We tested each
mutant receptor for carisoprodol direct gating potency and efficacy. Similar to valine
substitution at α1 (L415) position, L415S, L415G, L415W and L415C all decreased maximal
gating efficacy (to 5.5 ± 1.2, 9.1 ± 1.6, 17.8 ± 4.1, and 18.0 ± 1.6 % of saturating GABA
current, respectively). Potency to carisoprodol was generally unaffected, with the exception
that the L415W mutant induced a three-fold rightward shift in EC50 (Fig 4 A, B, C and Table
2). The presence of T, Y, I or R had no effect on either carisoprodol efficacy or potency.
Correlation analysis showed positive and negative correlations of amino acid volume and
polarity at the 415 position with carisoprodol direct gating efficacy (Fig. 5). These data
demonstrate the nature of the amino acid side chain at α1(415) position is critical for the
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direct gating effect of carisoprodol. In addition, an increase in GABA EC50 correlated
negatively with carisoprodol efficacy (Fig. 5F).
The α1 (L415S) mutation does not affect allosteric modulation by carisoprodol or direct
activation by pentobarbital
To further assess the extent to which the α1(L415) residue may be differentially
involved in direct gating action allosteric modulatory effects of carisoprodol, we tested if the
L415S mutation, which effectively obliterated the ability of carisoprdol to directly gate the
receptor (Fig. 4), had an effect on allosteric potentiation.

In α1(L415S)βγ2 receptors,

carisoprodol potentiation of GABA EC20 currents differed in neither maximum potentiation
nor potency when compared to wild type receptors (439.45 ± 49.4% potentiation and EC50
of 89.5 ± 15 M, n =7, in α1(L415S)βγ2 receptors compared to 474.75 ± 53.4% and 102.2
± 16 M, n =5 in wild type receptors, Fig. 6A, B). As a further assessment of the specificity
of the L415S mutation, we evaluated if it had any effect on direct gating by pentorbarbital.
Direct gating by 1 mM pentobarbital was not significantly different in α1(L415S)βγ2
receptors compared to wild type receptors (current amplitude in comparison to saturating
GABA was 70.2 ± 4.2%; n = 5 and 84.1 ± 6.4%; n = 7 in mutant and wild type receptors,
respectively (Fig 6. C and D). Thus effects of the L415S mutation are not due to non-specific
effects on the ability of direct-gating ligands to activate the channel.
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DISCUSSION
In a recent report (Kumar et al., 2015), we found that direct gating effects of the
skeletal muscle relaxant carisoprodol were reduced in α3βγ2 GABAA receptors, compared
to those expressing any other  subunit variant (1-2, 4-6). Here, we identified  subunit
TM4 residues, in particular 1415 (equivalent to 3440), that are critical for direct gating,
but not allosteric modulatory, effects of carisoprodol (Fig 1). Mutation of the native 3 440V
residue to the L residue found in the 1 subunit (V440L) resulted in a significant
enhancement of carisoprodol-gated current; the converse mutation (L415V), had the opposite
effect (Fig 2 and 3). Subsequent evaluation of a series of mutations resulted in the following
rank order effect on carisoprodol gating efficacy (L = I = T = R > Y > W = C = V > G > S),
and correlation analysis demonstrated that both amino acid volume and polarity are important
determinants of this position’s effect on carisoprodol direct gating (Fig 5). The presence of a
hydrophobic residue tended to correlate with enhanced carisoprodol gating, although this
effect did not reach statistical significance.

Interestingly, except for tryptophan (which

caused a 3-fold increase in carisoprodol direct gating EC50), none of the introduced mutants
affected potency of carisoprodol’s direct gating effect; the action was nearly exclusively an
effect on efficacy.
Transmembrane 4 residues of the α1 subunit have been shown to be involved in
allosteric modulatory effect of other GABAA receptor ligands, such as neurosteroids and
anesthetics (Hosie et al., 2006; Jenkins et al., 2002). Homology modeling has shown that
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N407 and Y410 donate a hydrogen bond to the ketone group of THDOC, and contribute to
the binding pocket of neurosteroids. Substitution of polar residues to hydrophobic amino
acids at N407A and Y410F reduced THDOC potency significantly (Hosie et al., 2006).
Indeed, L415 itself has been implicated in effects on anesthetic agents. In a tryptophan
scanning study of TM4, it was found that introduction of tryptophan at position 415 (L415W)
of the 1 subunit produced a significant decrease in the ability of the anesthetics halothane
and chloroform to potentiate GABA-gated currents (Jenkins et al., 2002). It is possible TM
domains forms an important allosteric modulatory site on GABAA receptors. However, our
results would seem to rule out the potential involvement of the TM4 domain 415 position, as
the (L415S) mutation did not affect allosteric potentiation of GABA currents (Fig 6). These
results are consistent with our contention that distinct sites exist for the allosteric modulatory
and direct gating effects of carisoprodol.
Previous molecular and behavior studies of carisoprodol have shown characteristics
of barbiturate-like effects. Both ligands directly gate, allosterically modulate, and inhibit the
receptor (at high concentrations).

More notably, in drug discrimination studies, the

barbiturate pentobarbital substituted for the discriminative stimulus effects of carisoprodol
in carisoprodol-trained rats. In addition, the barbiturate antagonist bemegride blocked the
locomotor depression effect of carisoprodol in mice, and also antagonized carisoprodol-gated
currents in HEK293 cells expressing GABAA receptors (Gonzalez et al., 2009). These
findings suggested that behavior and molecular action of carisoprodol may be mediated by a
barbiturate-like mechanism of action on GABAA receptors. However, in the present study
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the α1(L415S) mutation did not affect the ability of pentobarbital to directly gate GABAA
receptors. In addition, a rho receptor (wild type is insensitive to barbiturates) mutation that
confers sensitivity to barbiturate did not confer sensitivity to carisoprodol (Gonzalez et al.,
2009). Thus, although previous studies have shown barbiturate-like action of carisoprodol,
collectively the data support distinct binding sites or functional domains for carisoprodol
versus barbiturate direct gating effects in GABAA receptors. The actions of neurosteroids
are also comparable to carisoprodol. A threonine in position 236 of the 1 subunit (T236)
has been shown to be involved in direct gating of neurosteroids, as mutation of this residue
to I greatly attenuates sensitivity to the neurosteroid THDOC (Hosie et al., 2006). In separate
experiments, we tested whether the α1(T236I) mutation affected carisoprodol direct gating
actions. We found this mutation did not produce any change in carisoprodol efficacy relative
wild type receptors. Thus, the site of action for carisoprodol appears to also be distinct from
that of neurosteroids.
Our subunit-dependent studies of carisoprodol have also demonstrated significant
influence of the β subunit isoform in direct gating and allosteric modulatory effects of
carisoprodol (Kumar et al., 2015). Receptors expressing the β1 subunit showed highest
efficacy for direct gating, whereas β2-containing receptors confer enhanced allosteric
modulatory properties. The TM2 15’ residue lies toward the extracellular aspect of the
channel, and faces away from the channel pore; this residue in the β2 subunit (N265) has
been shown to be involved in alcohol and general anesthetics actions at GABAA receptors
(McCracken et al., 2010). Mutation of the β2 asparagine to methionine (N265M) reduced
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the direct gating currents of propofol, alphaxolone and etomidate, and decreased allosteric
potentiation by etomidate, propofol, enflurane, isoflurane, butanol and octanols (Siegwart et
al., 2003; Zeller et al., 2007b). Interestingly, TM2 of β subunit isoforms is highly conserved.
An exception is the 15’ residue, which is S in the β1 subunit. In preliminary studies in our
lab, mutation of the β1 TM2 15’ serine to the corresponding β2 subunit residue (asparagine,
N) decreased the direct gating efficacy of carisoprodol to 22.4 ± 4.4 for α1β1(STM215’N)γ2
receptor significantly from 62.2 ± 1.8 for α1β1γ2 wild type receptors. Based on our model
of the TM domains of the GABAA receptor (Fig. 7), it is unlikely carisoprodol docks between
the 265 residue of the 2 subunit and 415 of the 1 subunit. The involvement of the TM2
15’ position in a diverse array of ligands suggests its effects are more likely on transduction,
as opposed to forming part of a binding site for multiple and diverse ligands. A complete
understanding of the binding pocket for carisoprodol requires further exploration.
It is known that addictive drugs hijack the reward system by increasing dopamine
levels in mesolimbic system (Luscher and Ungless, 2006). Dopaminergic neurons in the
ventral tegmental area (VTA) express α3-containing GABAA receptors and the GABAergic
interneurons in the VTA express α1-containing receptors (Tan et al., 2010). Diazepam
binding to the α1-containing GABAA receptors on GABAergic VTA neurons leads to a
reduction of the activity of these cells, and thus reduced release of GABA, which results in
a disinhibition of the dopaminergic VTA neurons (Rudolph and Knoflach, 2011). In turn,
this results in an increase in dopamine release in the ventral striatum (Heikkinen et al., 2009).
These studies verified the α1 GABAA receptor subtype in the mesolimbic dopaminergic
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system is involved in addiction. Further, behavior studies in mice with mutation of a residue
key for benzodiazepine’s effects have shown physiological effects of this agent are GABAA
receptor subunit-dependent. The α1(H101R) knock-in mice showed absence of sedative
effects of diazepam but anxiolytic effects were not affected (Rudolph et al., 1999). If the
mutation was instead present in the 2 subunit α2(H101R), the anxiolytic action of diazepam
was absent, its myorelaxant actions (which are observed at higher doses than anxiolytic
effects) were reduced, but its sedative action was intact (Low et al., 2000). In α3(H126R)
and α5(H105R) mice, the myorelaxant action of diazepam was reduced without altering
sedative and anxiolytic actions (Crestani et al., 2001). Moreover, the development of
tolerance to the sedative action of benzodiazepines has been linked to α5-expressing GABAA
receptors (van Rijnsoever et al., 2004).
The goal of our present study was to identify key amino acid residues that are
involved in actions of carisoprodol at GABAA receptors. We found that α1(L415) of
transmembrane domain 4 of the GABAA receptor is involved in direct gating action of
carisoprodol, and identified physicochemical traits that are important for this effect.
Mutation of this residue did not impact allosteric modulatory effects of carisoprodol, and it
also had no effect on the ability of the barbiturate pentobarbital to directly gate the receptor.
These results are consistent with our contention that carisoprodol mediates these two actions
through distinct, likely novel, sites on the GABAA receptor.
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Table III-1. Influence of GABAA receptor α3 TM4 amino acids mutation to
corresponding α1 amino acids on GABA EC50 values, carisoprodol direct activation
and allosteric modulation. Carisoprodol direct gating activation at 3mM is normalized to
saturated GABA current, whereas carisoprodol modulation effect to potentiate GABA-gated
current is normalized to GABA EC20 current. Each data point represents the mean ± S.E.M
of n cells. *, p < 0.05; **, p < 0.01 relative to wild type α3β2γ2 GABAA receptors.
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GABAAR
Configuration

GABA EC50

CSP gating
(% of GABA max)

α3 WT

(μM)
34.8 ± 2.1

n
6

3mM
08.5 ± 1.1

α3(V440L)

07.5 ± 0.9 **

7

α3(I419L/I423A)

18.1 ± 2.2*

α3(I419L/I423A/V440L) 15.8 ± 5.0 *

CSP modulation
(% of GABA EC20)

n
11

300 µM
235 ± 35

n
6

37.6 ± 3.5**

9

301 ± 14

5

9

40.8 ± 2.4**

8

252 ± 14

4

6

35.9 ± 3.9**

10

156 ± 22

6

TABLE III-1
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Table III-2. Influence of GABAA receptor α1 TM4 residues mutation to corresponding
α3 amino acids and α1 (L415) amino acid substitution on GABA EC50 values and
carisoprodol direct activation properties.

Carisoprodol direct gating activation is

normalized to saturated GABA current whereas carisoprodol modulation effect to potentiate
GABA-gated current is normalized to GABA EC20 current. Each data point represents the
mean ± S.E.M of n cells. *, p < 0.05; **, p< 0.01 relative to wild type α1β2γ2 GABAA
receptors.
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GABAAR
Configuration

GABA EC50

CSP Direct gating
(% of GABA max)

α1 WT

(μM)
35.5 ± 0.6

n
5

Maximum
Efficacy
41.8 ± 2.4

α1(L394I)

50.8 ± 4.4

4

40.6 ± 4.6

559 ± 50

6

α1(A398I)

35.2 ± 4.1

5

36.1 ± 2.9

617 ± 83

6

α1(L415V)

89.0 ± 2.2**

5

17.7 ± 3.1**

826 ± 24

9

α1(L394I/A398I)

27.0 ± 3.4

3

42.0 ± 5.7

443 ± 28

9

α1(A398I/L415V)

68.4 ± 4.2 **

3

22.6 ± 1.8**

456 ± 40

5

α1(L394I/L415V)

27.5 ± 3.1

3

20.5 ± 3.2**

864 ± 21

9

α1(L394I/A398I/L415V)

44.1 ± 2.4

7

18.2 ± 4.5**

380 ± 20

7

α1(L415C)

39.4 ± 4.0

4

18.0 ± 1.6**

697 ± 41

9

α1(L415W)

47.7 ± 2.3

3

17.8 ± 4.1**

α1(L415G)

68.0 ± 4.3**

4

09.1 ± 1.6**

545 ± 10

5

α1(L415S)

65.0 ± 4.2**

7

05.5 ± 1.2**

651 ± 24

13

α1(L415T)

41.0 ± 2.1

4

37.1 ± 4.4

533 ± 41

9

α1(L415Y)

45.0 ± 3.2

4

25.4 ± 3.8

807 ± 55

6

α1(L415I)

40.3 ± 2.2

4

31.9 ± 4.1

450 ± 30

7

α1(L415R)

43.4 ± 5.2

4

32.6 ± 4.6

492 ± 24

4

EC50(µM)
685 ± 32

n
15

2056 ± 122**

6

TABLE III-2
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Figure III-1. GABAA receptor structure and alignment of transmembrane 4 amino acid
residue of α(1-6) GABAA receptor subunits. A, Top view of GABAA receptor,
representing arrangement of α1, β2 and γ2 subunits and GABA and benzodiazepine (BDZ)
binding sites. B, Lateral view of GABAAR subunit illustrating, 4 transmembrane domains,
the extracellular N-terminus, the C-terminus and the intracellular loop. C, Aligned Amino
acid sequence of TM4 region of human α subunit (α1-6) isoforms showing conserved (*)
and non-identical (red) amino acids.
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Figure III-2. Influence of 3 subunit TM4 residues mutation on direct activation and
allosteric modulation by carisoprodol. A, representative traces demonstrating carisoprodol
(CSP) activates human 322 WT and 3(V440L)22 GABAARs. Single mutation of
V440 at TM4 of α3 to L, which is present in α1-expressing GABAARs, increased CSP direct
gating potency significantly. B, bar graphs summarizing carisoprodol direct gating currents
for human α3-, α3(V440L)-, α3(I419L/I423A)-, α3(I419L/I423A/V440L) and 122
GABAARs. Single and combined mutation of TM4 domains of α3 to those present in α1
subunit significantly increased the direct gating potency of carisoprodol as compared to WT
α3 receptors. Carisoprodol-gated currents are normalized to currents elicited by saturated
GABA concentration (1 mM). C, representative traces demonstrating the potentiation of
GABA-gated (EC20) currents from human 322 WT and α3(V440L)22 GABAARs by
carisoprodol. D, concentration-response curves for the allosteric modulation of GABA-gated
currents from human α3-, α3(V440L)-, α3(I419L/I423A)-, α3(I419L/I423A/V440L) and
122 GABAARs. Mutation of TM4 domains of α3 to those present in α1 subunit did not
increased allosteric modulation efficacy of carisoprodol significantly as compared to WT α3
receptors. Carisoprodol potentiated currents are normalized to currents elicited by GABA
EC20 concentrations. Each data point represents the mean ± S.E.M. of a minimum of three
cells. **, p< 0.01, *, p< 0.05.
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Figure III-3. Influence of the α1 subunit TM4 residues mutation on direct activation by
carisoprodol. A, representative traces demonstrating carisoprodol (CSP) activates human
1β22 WT and 1(L415V)22 GABAARs. Corresponding reverse mutation of L415 at
TM4 of α1 to V (present in the α3 subunit) decreased carisoprodol direct gating potency
significantly, confirming involvement of TM4 residue L415 in direct gating. B, bar graphs
summarizing carisoprodol direct gating currents for human α3-, α1(L394I)-, α1(A398I)-,
α1(L415V)-,

α1(L394I/A398I)-,

α1(L394I/L415V)-,

α1(A398I/L415V)-,

α1(L394I/A398I/L415V) and 122 GABAARs. All α1- GABAARs containing L415V
mutation showed decreased CSP direct gating potency as compared to WT 1β22
GABAARs. Carisoprodol-gated currents are normalized to currents elicited by saturated
GABA concentration (1mM). Each data point represents the mean ± S.E.M. of a minimum
of three cells. **, p< 0.01*.

141

A
CSP (M)
GABA (1mM)

1000

3000

α1WT

1000

α1(L415V)

250 pA

250pA
10s

CURRENT AMPLITUTE
(% OF MAXIMAL GABA CURRENT)

10s

B

3000

70
60
50

1 WT
1(L394I)
1(A398I)
1(L415V)
1(L394I\A398I)

1(L394I\L415V)
1(A398I\L415V)
1(L394I\A398I\L415V)
3 WT

40
30


20


10



  







0
3000
1000
CARISOPRODOL (M)

FIGURE III-3.
142

Figure III-4. Influence of the 1 subunit TM4 L415 mutations on carisoprodol direct
gating potency and efficacy. A, representative traces demonstrating carisoprodol (CSP)
activates human 1(L415S)22 GABAARs. Carisoprodol reached saturation at 5 mM
concentration and blocking effects started becoming prominent. B, concentration-response
curves for the direct gating effect of carisoprodol from human α1(L415S)-, α1(L415V)-,
α1(L415G)-, α1(L415W)-, α1(L415C)- and 122 GABAARs. These 5 mutations all
decreased carisoprodol efficacy significantly without affecting carisoprodol EC50, expect for
α1(L415W) mutant which increased EC50 3-fold relative to wild type receptors. C. Bar
graphs summarizing carisoprodol (CSP) direct gating currents for human α1 WT-,
α1(L415I)-, α1(L415T)-, α1(L415R)-, α1(L415Y)-, α1(L415W)-, α1(L415V)-, α1(L415C), α1(L415G)-, α1(L415S)22 GABAARs. Carisoprodol-gated current reached saturation at
5 mM; receptors containing α1 (L415T/R/Y/I) mutant residue did not affect carisoprodol
direct gating efficacy and thus carisoprodol EC50 values were not calculated. Carisoprodol
gated currents are normalized to currents elicited by saturated GABA concentration (1 mM).
Each data point represents the mean ± S.E.M of a minimum of three cells. **, p< 0.01.
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Figure III-5. Physiochemical relation of 1 415 residue with carisoprodol direct gating
efficacy, GABA EC50 and GABA EC50 with carisoprodol efficacy. Correlations with
carisoprodol efficacy with α1(415) position amino acids A, Hydropathy; B, Volume; C,
Polarity. Correlations with GABA EC50 with amino acids D, Volume and E, Hydropathy;
F, Correlations of α1 mutant GABA EC50 with carisoprodol efficacy. Both amino acid
volume and polarity at the 415 position were correlated with carisoprodol efficacy. Each
data point represents the mean ± S.E.M of a minimum of three cells. *, p < 0.05.
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Figure III-6 Influence of the alpha1 subunit TM4, L415S mutation on allosteric
modulation by carisoprodol and pentobarbital direct activation. A, representative traces
demonstrating the potentiation of GABA-gated (EC20) currents from human α1(L415S)22
GABAARs by carisoprodol (CSP). B, concentration-response curves for the allosteric
modulation of GABA-gated currents from human wild type α122 and α1(L415S)22
GABAARs. Mutation of leucine to serine at α1(415) residue, did not affect allosteric
modulation by carisoprodol, confirming the amino acid at position 415 is solely involved in
the direct gating effects. Carisoprodol-potentiated currents are normalized to currents elicited
by GABA EC20 concentration. C, representative traces demonstrating pentobarbital (1mM)
activation of human 1(L415S)22 GABAARs. D, bar graphs summarizing pentobarbital
direct gating currents for human wild type α122 and α1(L415S)22 GABAARs. Mutation
of leucine to serine at α1(415) residue, did not affect direct activation by pentobarbital on
GABAARs. Pentobarbital-gated currents are normalized to the currents elicited by saturating
concentration of GABA (1 mM). Each data point represents the mean ± S.E.M. of a minimum
of three cells.

147

A

CSP (M)
GABA (EC20)

100

C PB (M)

300

1000

GABA (1mM)

α1(L415S)

α1(L415S)

100 pA
100pA

10s

10s

B
CURRENT AMPLITUDE
(% OF GABA EC20)

550

CURRENT AMPLITUTE
(% OF MAXIMAL GABA CURRENT)

D
1(L415S)
1 WT

500
450
400
350
300
250
200
150
100
10

100
CARISOPRODOL (M)

1000

100
80
60
40
20
0

1(L1S)22
122
PENTOBARBITAL (1mM)

FIGURE III-6
148

Figure III-7. Homology molecular model of GABAA receptor. A, Side view illustrating
alpha subunits in red, beta subunits in blue and gamma subunit in yellow. B, Highlighted
residue leucine 415 of α1 subunit, potential amino acid involved in direct gating action of
CSP.
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CHAPTER IV
SUMMARY AND DISCUSSION
Carisoprodol is a centrally-acting skeletal muscle relaxant frequently prescribed for
acute musculoskeletal conditions (Elder, 1991). Recreational use of carisoprodol is an
increasing problem (Bramness et al., 2004; Bramness et al., 2007; Ni et al., 2007).
Considering its alarming rate of abuse and subsequent consequences, carisoprodol was
scheduled (schedule IV) at the federal level effective January 11, 2012 (DEA, 2011). Given
the present and potential dangers posed by carisoprodol abuse, it is of crucial importance to
determine how this drug mediates its effects. Until recently, it was widely accepted that the
sedative and muscle relaxant effects of carisoprodol were due predominantly to its
metabolite, meprobamate. However, it is now clear that carisoprodol itself modulates and
directly gate GABAARs. Thus, our studies were aimed at contributing to the current
knowledge regarding the mechanism of action of carisoprodol as a therapeutic agent and as
a drug of abuse.
Subunit-dependent studies (Chapter II) have shown carisoprodol’s actions on
GABAA receptors are influenced by subunit isoforms present in a receptor. Carisoprodol is
most efficacious on α1 subunit containing GABAA receptors for potentiating the GABAgated currents. This may underlie the ability of carisoprodol in enhancing the sedative effects
of CNS depressants, contributing to its potential for abuse. The direct gating action of
carisoprodol on GABAA receptor is generally comparable regardless of α subunit isoform,
however, receptors incorporating the α3 subunit showed significantly lower direct gating
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efficacy and affinity. Presence or absence of the γ2 subunit did not affect the ability of
carisoprodol to directly gate or allosterically modulate the receptor. Regarding β subunit
isoforms, incorporation of β1 subunit conferred highest efficacy for direct activation relative
to maximum GABA currents, while presence of the β2 subunit conferred highest efficacy for
allosteric modulation of the GABA response. In δ subunit expressing extrasynaptic α1β3δ
and α4β3δ receptors, carisoprodol is more efficacious than GABA as a direct gating agonist
and allosterically potentiated both saturated and sub-saturating GABA currents. We also
studied the voltage-dependent effect of carisoprodol on GABAA receptors. We found,
allosteric modulatory effect of carisoprodol is voltage sensitive while direct gating effect is
voltage independent. These results suggest carisoprodol interacts with distinct sites to
allosterically modulate and directly gate the GABAAR, and subunit isoform influences these
effects. As mentioned earlier, physical dependence is more prone to develop with drugs that
interact with a broader collection of GABAAR subtypes (Licata and Rowlett, 2008), the high
efficacy of carisoprodol for both direct and allosteric effects on α1-containing receptors,
coupled with its ability to interact with GABAAR subtypes, is consistent with its high abuse
potential (Rudolph and Knoflach, 2011).
After gaining information regarding carisoprodol’s GABAAR subunit selectivity,
we identified the subunit amino acid domains involved in direct gating and allosteric
modulation effects of carisoprodol (Chapter III). To gain insight into the molecular
mechanism of action of carisoprodol and specific amino acid domains involved in the direct
gating and allosteric modulatory effects of carisoprodol, we aligned the amino acid sequence
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of α subunit isoforms and took advantage of site directed mutagenesis. We identified several
residues in TM4 of the α3 subunit that are unique compared to residues present in all other α
subunits. We tested their involvement in the ability of carisoprodol to directly gate the
GABAAR by mutating these residues to those present in the α1 subunit, individually and in
combination, and assessing effects on carisoprodol elicited gating. In single and combined
mutations expressing the α3(V440L) residue mutation, carisoprodol gained significant
capacity to directly gate the receptor compared to α3 WT receptors. In contrast, the V440L
mutation did not affect carisoprodol's ability to allosterically modulate GABA-activated
currents. These results demonstrate amino acid residues in TM4 of the GABAA receptor are
critical in the direct gating, but not allosteric modulatory actions of carisoprodol
To confirm the involvement of TM4 residues in carisoprodol direct gating, we did
corresponding reverse mutations in α1 subunit, individually and in combination, and tested
to see if these mutations decrease carisoprodol sensitivity of α1β2γ2 receptors. In single and
combined mutations that included the TM4 L415 residue, direct gating activity of
carisoprodol was significantly reduced. Specifically carisoprodol direct gating efficacy
reduced to 18% of α1(L415V)β2γ2 receptors from 42% of WT α1β2γ2 receptors. To further
investigate the role of the alpha1 TM4 415 region, we substituted the wild type leucine with
eight different amino acids one by one based on size, volume, polarity, hydrophobicity and
hydrophobicity to study the effect of physio-chemical properties of amino acid side chains
on carisoprodol direct gating affinity and efficacy. Insertion of isoleucine, arginine, tyrosine
and threonine at alpha1 415 position did not affect carisoprodol direct gating efficacy,
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however, insertion of cysteine, tryptophan, valine, glycine and serine significantly decreased
the direct gating efficacy relative to wild type. Interestingly, substitution of leucine with
serine decreased direct gating efficacy to 5.5% from 42% (WT) but insertion of threonine
did not affect carisoprodol direct gating efficacy suggesting orientation of hydroxyl and
isopropyl group at alpha1 415 position plays a critical role in carisoprodol direct gating
efficacy. In physio-chemical analysis of substituted amino acid side chain properties with
carisoprodol’s direct gating efficacy, we concluded that the volume and polarity of amino
acid side chain at 415 position of α1 subunit significant affect carisoprodol direct gating
efficacy. To further confirm the involvement of α1 (415) domain only in direct gating action
and not in allosteric modulatory effect, we tested α1 (L415S) mutant for allosteric
modulatory effect of carisoprodol and found insertion of serine at α1(415) position does not
affect the allosteric modulatory effect of carisoprodol. The α1 (L415S) mutation also did not
affect pentobarbital direct gating efficacy. Thus, α1 (L415) amino acid residue is solely
involved in the direct gating effect of carisoprodol but not in the allosteric modulation. These
data confirmed carisoprodol interacts with distinct sites to allosterically modulate and
directly gate the GABAA receptors.
The central nervous system adapts to its ambience constantly and it is not surprising
that prolonged exposure to drug molecules elicits compensatory changes at the receptor level.
A single intoxicating dose of alcohol results in down regulation of α4βδ receptors in
hippocampal pyramidal neurons leading to generation of acute tolerance (Hemby et al., 2006;
Shen et al., 2011). With a few more doses of alcohol, internalization of α1 subunit receptors
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at synapses occurs, leading to mobilization of α4 subunit receptors to the synapses from
extrasynaptic region. Down regulation of α4βδ receptors at extrasynaptic region is
compensated by overexpression of α4βγ receptors to supplement tonic inhibition (Liang et
al., 2007). This mobilization of receptors is reversible, however, during chronic consumption
of alcohol it becomes irreversible resulting in alcohol dependence (Liang et al., 2007). With
chronic opiate exposure and following withdrawal, GABAARs signaling transition from
inhibitory to excitatory in ventral tegmental area, contributing to opiate dependence
(Laviolette et al., 2004). Carisoprodol abuse is also associated with dependence, tolerance,
and withdrawal (Heacock and Bauer, 2004; Reeves et al., 2012; Reeves et al., 2007). We did
not explore the changes associated with chronic carisoprodol administration, but it is likely
that carisoprodol elicits fundamental changes in the GABAergic system. Moreover, chronic
administration of drugs that target GABAARs reorganize the GABAergic system
transmission and may lead to tolerance; the extent of modification depends upon the dose
and duration of drug exposure (Korpi et al., 2002; Wafford, 2005). This event may be due to
uncoupling of allosteric sites (Ito et al., 1996), modifications in receptor turnover (Kumar et
al., 2003; Pericic et al., 2003), or desensitization. Whether expression of a subunit is
upregulated or down regulated in response to chronic use varies with its location in the brain
(Wafford, 2005). In some studies, down regulation of the 1 subunit has been observed,
which is generally accompanied by compensatory up regulation of other subunits (Ito et al.,
1996; Wafford, 2005). We have shown carisoprodol is most efficacious on 1-containing
receptors and less efficacious on other receptor configurations, displacing 1 subunits with
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other isoforms may diminish the physiological effects of carisoprodol. The shift towards
GABAAR configurations that are less sensitive to carisoprodol’s effects may contribute to
tolerance. Such compensatory mechanisms associated with chronic activation of the
GABAergic system are analogous to inhibitory dysregulation. Thus, abrupt cessation of the
drug is likely to precipitate withdrawal symptoms as the central nervous system attempts to
restore normal inhibitory function.
While carisoprodol remains an efficacious choice for the treatment of acute low
back pain, its abuse liability has become a major concern in recent years, and ready
availability and low cost has made it a drug of choice among abusers. Scheduling of
carisoprodol in Norway resulted in a rapid and significant decline in the detection of
carisoprodol in autopsies and driving under the influence occurrences (Hoiseth et al., 2009).
As carisoprodol is now controlled in the United States at the federal level, it is likely the
incidence of abuse and fatalities will also decline here. Physician awareness regarding
potential dangers associated with abuse of carisoprodol and its metabolite meprobamate
should also improve with the recent scheduling. However, considering the fact that low back
pain has been one of the top five reasons for physician visits in the United States for decades
(Witenko et al., 2014), the need to develop a safe and efficacious agent for this substantial
medical need is clear. Also, while the number of reports regarding carisoprodol abuse
continues to increase, there has been little progress in the treatment of carisoprodol
dependence and withdrawal. At present, treatment consists of brief courses with
benzodiazepines or phenobarbital to combat anxiety and insomnia. Further, treatment of
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carisoprodol overdose is complicated as it is often characterized by agitation and seizures,
and the administration of anticonvulsants and sedatives exacerbates CNS depression, leaving
supportive therapy as a preferred course of action. The insights gained in our study of
carisoprodol’s molecular action should prove useful in better understanding how to treat
misuse, and in development of improved muscle relaxants with reduced abuse liability.
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FUTURE DIRECTIONS
In the present study we concluded that distinct amino acids or binding sites are
involved in direct gating and in the allosteric modulation action of carisoprodol. We
identified the leucine 415 residue at TM4 of α1 subunit is critical in the direct gating action
of carisoprodol. Docking of carisoprodol on a molecular model of GABAA receptors will
provide further insights into the binding pocket amino acids of carisoprodol. However, it is
still unclear whether L415 is involved in the binding pocket of carisoprodol of GABAA
receptors or if it is involved in the conformational wave leading to channel gating called
coupling. Ligand binding assays, single channel analysis, and substituted cysteine
accessibility method (SCAM) experiments at mutant α1(L415S)β2γ2 GABAA receptors
would clarify the importance of this residue in carisoprodol’s direct gating action. Single
channel (open probability) analysis would also provide critical information on whether
channel opening gated by carisoprodol is more like pentobarbital (long duration opening) or
benzodiazepines (burst openings) (MacDonald et al., 1989; Steinbach and Akk, 2001;
Thompson et al., 1999).
It cannot be denied that the allosteric modulatory effect of carisoprodol is highly
important in physiological actions of carisoprodol and we have shown that carisoprodol is
highly efficacious at potentiating GABA-gated currents. In the present study, that we did not
identify the molecular domains involved in the allosteric modulatory effect of carisoprodol.
However, we demonstrated that carisoprodol is highly efficacious on α1 subunit containing
receptors compared as to other isoforms of α subunit and the fact the α1 subunit GABAA
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receptors are involved in the addiction and sedative mechanisms of benzodiazepines (Ator,
2005; Tan et al., 2010). It is very critical to determine the molecular mechanism of allosteric
modulation by carisoprodol. We have identified two amino acids in the pre-TM1 region
(G200 and V202) and one amino acid at the N- terminal (F45) region of α1 subunit which
are unique compared to the rest of the α subunit isoforms in the extracellular domains of
GABAA receptor. Investigation of these amino acids may provide critical information about
carisoprodol’s allosteric modulation binding site.
Our study demonstrates that GABAA receptor subtype isoforms influence
carisoprodol’s action and the molecular sites where carisoprodol can interact to modulate
GABAA receptor functions. Replication of our experiments in an in-vivo model would allow
us get complete knowledge of carisoprodol’s subunit-dependent physiological effects.
Therefore, it is critically important to investigate which of the GABAAR subunit isoforms
account for specific behavioral actions of carisoprodol. The extensively used techniques to
study specific GABAAR subunit isoform with behavior are genetic deletion of a subunit
isoform in a knockout mouse and viral delivery of inhibitory RNAs or other RNAs to
generate knockdown in specific brain regions. The knockout model of specific GABAA
receptor subunits have been studied for alcohol research (Blednov et al., 2012). The α1 and
α2 subunit knockin mice showed α1 GABAA receptors are involved in alcohol tolerance
and physical dependence while α2 GABAA receptors with taste aversion, alcohol
consumption, and motor stimulation (Hemby et al., 2006; Liang et al., 2007; Shen et al.,
2011). Knockdown of α4 subunit together with δ subunit in the nucleus accumbens region
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of the mice brain have been shown to reduce the alcohol intake, suggesting a critical of role
extrasynaptic α4βδ GABAA receptors in alcohol intake reinforcement (Nie et al., 2011). As
mentioned earlier, behavioral effects of benzodiazepines have also been studied in mutant
mice, where diazepam was made insensitive on specific GABAA subunit isoforms by
mutating arginine to histidine at its conserved site of action on α1, α2, α3 and α5 subunit
containing receptors (Rudolph et al., 1999). Diazepam’s sedative, amnesic and
anticonvulsant effects were absent in α1(H101R) mutant mice. Mutant mice containing
α2(H101R) receptors showed absence of anxiolytic, motor-impairing and partly myorelaxant
effects while retaining sedative effects of diazepam. Also, it’s been shown that development
of tolerance to the sedative effects of diazepam in mice requires α5 GABAA subunit receptors
(van Rijnsoever et al., 2004). Further, α1 subunit containing GABAA receptors have been
shown to be involved in addictive properties of benzodiazepines (Tan et al., 2010). GABAA
receptor α subunit isoforms knockout mice would provide importance of each α GABAAR
subunit isoform in carisoprodol’s pharmacological effects. Also, α1(L415S) knock in mutant
mice will give insights into the role of the direct gating action of carisoprodol.
The ultimate goal of our study is to get critical information which will help in the
development of a better muscle relaxant with reduced or no abuse potential. GABAA receptor
subunit-selective compounds have been developed and studied widely. Zolpidem (brand
name Ambein) is a frequently prescribed sedative for sleep disorder that is selective for α1
GABAA receptors (Rowlett et al., 2005). L-838417, a partial agonist at α2, α3 and α5 and
antagonist at α1 GABAA was developed as an analog of benzodiazepines as a non-sedative
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anxiolytic (Rowlett et al., 2005). However, pharmacokinetic properties of this compound
were not promising (Scott-Stevens et al., 2005). As mentioned previously, a drug selective
primarily for α2 -expressing GABAA receptors would likely have less abuse potential and
fewer sedative effects (Rudolph and Knoflach, 2011). SL651498 is a selective agonist of α2
and α3 GABAA receptors and partial agonist at α1 and α5 GABAA receptors, which is under
development as non-sedative anxiolytic and muscle relaxant (Griebel et al., 2003; Whiting,
2006). As mentioned earlier, carisoprodol was developed as an analog of meprobamte
(replacing isopropyl group on one of the carbamyl nitrogens) suggesting lower abuse
liabilities and better muscle relaxation properties (Nebhinani et al., 2013) but recent evidence
confirms carisoprodol high abuse potential (Reeves et al., 2012). However, subunitdependence data has shown carisoprodol is more efficacious than meprobamate on GABAA
receptors (Kumar et al., 2012). These finding suggest carisoprodol would be a good candidate
to investigate its structure-activity relationship on GABAA receptor subunit isoforms.

168

REFERENCES
Ator NA (2005) Contributions of GABAA receptor subtype selectivity to abuse liability
and dependence potential of pharmacological treatments for anxiety and sleep
disorders. CNS spectrums 10(1): 31-39.
Blednov YA, Mayfield RD, Belknap J and Harris RA (2012) Behavioral actions of alcohol:
phenotypic relations from multivariate analysis of mutant mouse data. Genes,
brain, and behavior 11(4): 424-435.
Bormann J (2000) The 'ABC' of GABA receptors. Trends in pharmacological sciences
21(1): 16-19.
Bramness JG, Skurtveit S and Morland J (2004) Impairment due to intake of carisoprodol.
Drug and alcohol dependence 74(3): 311-318.
Bramness JG, Skurtveit S, Morland J and Engeland A (2007) The risk of traffic accidents
after prescriptions of carisoprodol. Accident; analysis and prevention 39(5): 10501055.
DEA (2011) Schedule of controlled substances: placement of carisoprodol into Schedule
IV, in 76 (Administration DE ed) pp 77330-77360, Federal Register.
Elder NC (1991) Abuse of skeletal muscle relaxants. American family physician 44(4):
1223-1226.
Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ and Dillon GH (2009)
Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo

169

studies. The Journal of pharmacology and experimental therapeutics 329(2): 827837.
Griebel G, Perrault G, Simiand J, Cohen C, Granger P, Depoortere H, Francon D, Avenet
P, Schoemaker H, Evanno Y, Sevrin M, George P and Scatton B (2003) SL651498,
a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment
for generalized anxiety disorder and muscle spasms. CNS drug reviews 9(1): 3-20.
Heacock C and Bauer MS (2004) Tolerance and dependence risk with the use of
carisoprodol. Am Fam Physician 69(7): 1622-1623.
Hemby SE, O'Connor J A, Acosta G, Floyd D, Anderson N, McCool BA, Friedman D and
Grant KA (2006) Ethanol-induced regulation of GABA-A subunit mRNAs in
prefrontal fields of cynomolgus monkeys. Alcoholism, clinical and experimental
research 30(12): 1978-1985.
Hoiseth G, Karinen R, Sorlid HK and Bramness JG (2009) The effect of scheduling and
withdrawal of carisoprodol on prevalence of intoxications with the drug. Basic &
clinical pharmacology & toxicology 105(5): 345-349.
Ito T, Suzuki T, Wellman SE and Ho IK (1996) Pharmacology of barbiturate
tolerance/dependence: GABAA receptors and molecular aspects. Life sciences
59(3): 169-195.
Korpi ER, Grunder G and Luddens H (2002) Drug interactions at GABA(A) receptors.
Progress in neurobiology 67(2): 113-159.

170

Kumar M, Nguyen JD, Gatch MB, Forster MJ and Dillon GH (2012) A comparison of
molecular mechanism of carisoprodol with its metabolite meprobomate on
GABAA receptors and assessment of its action on NMDA receptors, in Society for
neuroscience, New Orleans, Louisina.
Kumar S, Kralic JE, O'Buckley TK, Grobin AC and Morrow AL (2003) Chronic ethanol
consumption enhances internalization of alpha1 subunit-containing GABAA
receptors in cerebral cortex. J Neurochem 86(3): 700-708.
Laviolette SR, Gallegos RA, Henriksen SJ and van der Kooy D (2004) Opiate state controls
bi-directional reward signaling via GABAA receptors in the ventral tegmental area.
Nat Neurosci 7(2): 160-169.
Liang J, Suryanarayanan A, Abriam A, Snyder B, Olsen RW and Spigelman I (2007)
Mechanisms of reversible GABAA receptor plasticity after ethanol intoxication.
The Journal of neuroscience : the official journal of the Society for Neuroscience
27(45): 12367-12377.
Licata SC and Rowlett JK (2008) Abuse and dependence liability of benzodiazepine-type
drugs: GABA(A) receptor modulation and beyond. Pharmacology, biochemistry,
and behavior 90(1): 74-89.
MacDonald RL, Rogers CJ and Twyman RE (1989) Barbiturate regulation of kinetic
properties of the GABAA receptor channel of mouse spinal neurones in culture.
The Journal of physiology 417: 483-500.

171

Nebhinani N, Aggarwal M, Mattoo SK and Basu D (2013) Carisoprodol: an
underrecognized drug of abuse in north India. General hospital psychiatry 35(1):
89-92.
Ni K, Cary M and Zarkowski P (2007) Carisoprodol withdrawal induced delirium: A case
study. Neuropsychiatric disease and treatment 3(5): 679-682.
Nie H, Rewal M, Gill TM, Ron D and Janak PH (2011) Extrasynaptic delta-containing
GABAA receptors in the nucleus accumbens dorsomedial shell contribute to
alcohol intake. Proceedings of the National Academy of Sciences of the United
States of America 108(11): 4459-4464.
Pericic D, Strac DS, Jembrek MJ and Rajcan I (2003) Prolonged exposure to gammaaminobutyric acid up-regulates stably expressed recombinant alpha 1 beta 2 gamma
2s GABAA receptors. Eur J Pharmacol 482(1-3): 117-125.
Reeves RR, Burke RS and Kose S (2012) Carisoprodol: update on abuse potential and legal
status. Southern medical journal 105(11): 619-623.
Reeves RR, Hammer JS and Pendarvis RO (2007) Is the frequency of carisoprodol
withdrawal syndrome increasing? Pharmacotherapy 27(10): 1462-1466.
Rowlett JK, Platt DM, Lelas S, Atack JR and Dawson GR (2005) Different GABAA
receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of
benzodiazepine-like drugs in primates. Proceedings of the National Academy of
Sciences of the United States of America 102(3): 915-920.

172

Rudolph U, Crestani F, Benke D, Brunig I, Benson JA, Fritschy JM, Martin JR,
Bluethmann H and Mohler H (1999) Benzodiazepine actions mediated by specific
gamma-aminobutyric acid(A) receptor subtypes. Nature 401(6755): 796-800.
Rudolph U and Knoflach F (2011) Beyond classical benzodiazepines: novel therapeutic
potential of GABAA receptor subtypes. Nature reviews Drug discovery 10(9): 685697.
Scott-Stevens P, Atack JR, Sohal B and Worboys P (2005) Rodent pharmacokinetics and
receptor occupancy of the GABAA receptor subtype selective benzodiazepine site
ligand L-838417. Biopharmaceutics & drug disposition 26(1): 13-20.
Shen Y, Lindemeyer AK, Spigelman I, Sieghart W, Olsen RW and Liang J (2011)
Plasticity of GABAA receptors after ethanol pre-exposure in cultured hippocampal
neurons. Molecular pharmacology 79(3): 432-442.
Steinbach JH and Akk G (2001) Modulation of GABA(A) receptor channel gating by
pentobarbital. The Journal of physiology 537(Pt 3): 715-733.
Tan KR, Brown M, Labouebe G, Yvon C, Creton C, Fritschy JM, Rudolph U and Luscher
C (2010) Neural bases for addictive properties of benzodiazepines. Nature
463(7282): 769-774.
Thompson SA, Smith MZ, Wingrove PB, Whiting PJ and Wafford KA (1999) Mutation at
the putative GABA(A) ion-channel gate reveals changes in allosteric modulation.
British journal of pharmacology 127(6): 1349-1358.

173

van Rijnsoever C, Tauber M, Choulli MK, Keist R, Rudolph U, Mohler H, Fritschy JM
and Crestani F (2004) Requirement of alpha5-GABAA receptors for the
development of tolerance to the sedative action of diazepam in mice. The Journal
of neuroscience : the official journal of the Society for Neuroscience 24(30): 67856790.
Wafford KA (2005) GABAA receptor subtypes: any clues to the mechanism of
benzodiazepine dependence? Current opinion in pharmacology 5(1): 47-52.
Whiting PJ (2006) GABA-A receptors: a viable target for novel anxiolytics? Current
opinion in pharmacology 6(1): 24-29.
Witenko C, Moorman-Li R, Motycka C, Duane K, Hincapie-Castillo J, Leonard P and
Valaer C (2014) Considerations for the appropriate use of skeletal muscle relaxants
for the management of acute low back pain. P & T : a peer-reviewed journal for
formulary management 39(6): 427-435.

174

